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Pancreatic ductal adenocarcinoma (PDA), or pancreatic cancer, is 
currently the fourth leading cause of cancer deaths in the United States, and is 
projected to become the second leading cause surpassing those caused by 
breast, prostate, and colorectal cancers by the year 2030.  Surgical resection is 
the only cure for the disease; however, only 20% of patients are eligible for 
surgical resection at the time of diagnosis.  A hallmark of PDA that mediates its 
poor prognosis is the desmoplastic stroma, a major component of PDA’s 
dynamic tumor microenvironment (TME) that renders PDA refractory to radiation 
and chemotherapies.  
PDA tumorigenesis is initiated, propagated, and maintained by the 
expression of driver mutation KRAS, making mutant KRAS an ideal target for 
early stage disease intervention.  In addition to targeting neoplastic cells that 
express mutant KRAS, we must also target the recruited stromal compartment 
that is essential to PDA’s immunosuppressive, tumor-supportive TME.  The fibro-
inflammatory stromal matrix is comprised of cellular and acellular constituents 
that create a dense, non-permissive environment protecting the tumor from 
immune recognition and chemotherapeutic penetration.  Therefore, combination 
therapies that target transformed cells and stromal components administered 
during early PDA development will be the most promising solution to this lethal 
disease.   
Our studies aimed to investigate and ultimately modulate the epigenetic 
and immune mediated mechanisms that contribute to early PDA development in 
 iii 
order to intercept disease progression.  By expression profiling premalignant 
lesions, we uncovered novel microRNAs (miRNAs) whose levels are upregulated 
as a result of mutant KRAS activation.  We discovered that miR-21 and miR-224 
propel epithelial cell transformation and stromal cell activation altering their 
functional phenotypes in the early PDA TME, and that by endogenously inhibiting 
these miRNAs certain WT phenotypes can be restored.   
We also investigated whether administration of a mutant KRAS-targeting 
vaccine in combination with immunomodulatory agents and checkpoint blockade 
can alter specific inhibitory immune pathways in the early TME to impede 
premalignant progression.  Our results demonstrated that our combination 
vaccine-based therapy significantly reprograms the immunosuppressive TME by 
reducing the population of pro-carcinogenic T regulatory cells and expression of 
checkpoint molecules, leading to increased effector T cell activation, cytotoxic 
function, and generation of memory populations.  The reprogramming achieved 
by our combination therapy successfully delayed the progression of premalignant 
lesions in our endogenous mouse model of PDA.  Taken altogether, these 
studies reveal that the early PDA TME can be targeted on multiple levels, 
epigenetically and immunologically, in combination to intercept early disease 
development.    
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CHAPTER ONE: Novel miRNA regulation in an early progression model of 
PDA 
SUMMARY 
The success of current immunotherapies are dependent on infiltration and 
function of T cells within the tumor microenvironment (TME).  However, for many 
cancers, inflammatory and stromal cells provide formidable barriers to T cell 
access.  Emerging data suggests that the cellular barriers to T cell access and 
function are regulated by both genetic and epigenetic factors.  Identification of 
these regulators should provide new targets for enhancing immunotherapy. 
microRNAs (miRNAs) are short endogenous non-coding RNAs that are 
approximately 20 nucleotides in length that negatively regulate protein 
expression by inhibiting translation and/or by targeting mRNAs for degradation.  
Dysregulation of miRNA expression is important to the development of many 
cancers and although numerous studies have described the molecular alterations 
that are involved in PDA development and progression, few studies have 
investigated the miRNA profile and associated inflammatory changes within the 
TME from the earliest pre-malignant pancreatic intraepithelial neoplasias 
(PanINs) to PDA.   
The overall goal of this research is to construct a comprehensive profile of 
miRNA expression within the inflammatory and stromal cells that develop in the 
earliest PanIN lesions in the KrasG12D/+;Trp53R172H/+;Pdx-1-Cre (KPC) mouse 
model, an endogenous model that recapitulates human PDA tumorigenesis.  
Specifically, we aim to investigate the functional roles of key differentially 
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expressed miRNAs in establishing and propagating the earliest PanIN lesions 
within the TME via modulating the signaling between transformed ductal 
epithelial cells and the recruited cancer associated fibroblasts (CAFs) that 
comprise the majority of the cancer-supportive immunosuppressive desmoplastic 
stroma that characterizes PDA. 
We conducted miRNA microarray analysis to determine the levels of 750 
unique miRNAs in the pancreata of KPC mice ranging from 4 to 12 weeks of age 
(pre-PanIN1 to PDA).  miRNA expression was quantified by Taqman miRNA 
OpenArrays and confirmed by qPCR analysis.  Out of the 750 rodent miRNAs, 4 
miRNAs (miR-21, miR-16, miR-19b, and miR-224) were significantly upregulated 
throughout PDA development.  miR-21 and miR-224 are of particular interest for 
their regulation of targets in cancer promoting inflammatory pathways and 
epithelial-mesenchymal transition. 
To investigate the roles that miR-21 and miR-224 play in the developing 
TME, primary KPC pancreatic ductal epithelial and fibroblast cell lines were 
established via fluorescence activated cell sorting (FACS) in order to perform in 
vitro miRNA knock-in and knock-out studies.  qPCR of these primary cell lines 
show that miR-21 is significantly upregulated in KPC tumor cells and miR-224 is 
overexpressed in CAFs.  miRNA fluorescence in situ  hybridization (miR-FISH) 
was performed to examine the endogenous spatial expression of these two 
miRNAs throughout early TME progression.  miR-FISH revealed that miR-21 is 
expressed at low levels in normal pancreata, but is highly expressed particularly 
in ductal epithelial cells of late stage KPC pancreata and PDA.  Conversely, miR-
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224 is expressed by the infiltrating stromal compartment surrounding advanced 
lesions.  Stable lentiviral inhibition of miR-21 in KPC tumor cells reduced cell 
proliferation and migration, whereas overexpression of miR-224 in normal 
pancreatic fibroblasts increased their migratory capacity.  Additional studies are 
underway to further determine the functional roles of these miRNAs in PDA 
development and progression.  Such studies will elucidate potential miRNAs that 
can be targeted for novel PDA therapies or used as adjuvants for enhancing 
immunotherapy efficacy, while further revealing the molecular mechanisms of 

















PDA accounts for 90% of all pancreatic cancer types and is ranked fourth 
amongst all cancer-related deaths in the United States with an overall median 
survival of 4-6 months.1 PanIN lesions grades 1-3 are the most common 
precursors to invasive PDA.2  A hallmark of PDA is the presence of extensive 
desmoplastic reaction, or fibro-inflammatory stroma, that mediates its resistance 
to chemotherapies and results in poor prognosis.3,4  This dense desmoplasia is a 
major component of a dynamic TME that is composed of not only tumor epithelial 
cells, but also recruited fibroblasts, pancreatic stellate cells, 
inflammatory/immune cells, and extracellular matrix (ECM) proteins, that all serve 
to drive disease progression from early stage PanINs to PDA.5  The majority of 
the tumor volume is not composed of neoplastic cells, rather it predominantly 
consists of local dense desmoplastic reaction that involves proximal vital 
structures, which limits the complete excision of these tumors and precludes 85% 
of patients as candidates for surgical resection.6 
The KRAS driver mutation initiates PanIN formation and early 
development of the cancer-supportive TME via recruitment of the fibro-
inflammatory stroma.  Not only is mutant KRAS required for the initiation of 
PDA3,7, but it is necessary for the maintenance and continual propagation of the 
disease.3  KRAS mutation is one of the earliest catalytic events and most highly 
expressed mutation in PDA development present in over 90% of human PanIN1 
lesions and over 95% of PDA cases2, hence mutant KRAS serves as an 




Figure 1.1 PDA Progression Model  
Highlights the role of KRAS  driver mutation in ductal reprogramming to initiate 
PanIN formation and concurrent establishment of a dynamic TME.  Figure from 
Morris IV et al.8 
 
Activating mutations in the KRAS proto-oncogene unleashes a cascade of 
events that initiate tumorigenesis due to its critical role in many intracellular 
signal transduction pathways.  KRAS, a membrane-bound GTPase that is a 
member of the ras family of proto-oncogenes, once mutated is unable to 
hydrolyze GTP to GDP and therefore becomes constitutively active.  In human 
cancers, activating KRAS mutations are single amino acid substitutions 
predominantly at residues 12, 13, and 61 that render the GTPase constantly 
active.9  This gain-of-function mutation persistently activates all downstream 
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signaling pathways that trigger tumor initiation, progression, and malignant 
metastasis.5,10  Primary pathways that are upregulated are Raf/MEK/ERK and 
PI3K/Akt/mTOR pathways that result in increased cell proliferation, survival, and 
metabolic reprogramming.10,11  Hence many therapeutics have been developed 
to target KRAS directly, inhibit downstream KRAS effectors, or prevent the 
localization of KRAS to the plasma membrane.12  However, the clinical benefit of 
these therapeutics have been limited by cellular compensatory mechanisms, 
drug toxicities, and narrow windows of efficacy.12 
Tantamount to mutant KRAS’s ability to transform cells is its ability to 
establish a cancer-supportive TME that serves to maintain and propagate PDA 
progression.  Once ductal reprogramming is initiated, the transformed pancreatic 
epithelial cells expressing mutant KRAS also secrete many inflammatory 
cytokines such as Sonic Hedgehog (SHH), interleukin-6 (IL-6), interleukin-8 (IL-
8), prostaglandin E (PGE), and TGFβ that recruit the desmoplastic 
stroma.8,11,13,14  PGE directly activates proximal pancreatic stellate cells (PSCs), 
which in turn increases proliferative, migratory, and invasive potential of tumor 
cells in a paracrine fashion.5  Additionally, activated resident PSCs produce 
collagen and angiogenic factors in localized tissue.5,11  TGFβ is a key cytokine 
that increases fibrosis and ECM deposition by recruiting CAFs and PSCs to the 
site of tumorigenesis.6  These inflammatory signals generate a phenotypic 
response similar to that of wound healing in which fibrosis develops as a result of 
certain cell populations, mainly CAFs, that are recruited to the site of injury. 15,16  
Unlike the normal wound healing response, recruited CAFs remain activated and 
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increase the fibrotic stromal compartment that supports and propagates the 
developing tumor.16  In fact, studies utilizing a DNA vaccine expressing human 
fibroblast activation protein (FAPα) for the targeted immune-mediated eradication 
of CAFs successfully reduces tumor burden in a murine model of breast and 
colon cancer.17,18  80% of PDA tumor volume is comprised of stroma19, therefore 
CAFs, which are major components of the stroma, should be targeted along with 
tumor cells.  Our research aims to employ miRNA-mediated modulation of these 
two main cell types within the developing PDA TME. 
For accurate preclinical modeling of PDA, the dynamic TME must be 
endogenously recapitulated to examine intervention strategies for multiple 
components.  For our developmental studies, we utilized the 
KrasG12D/+;Trp53R172H/+;Pdx-1-Cre (KPC) mouse model that spontaneously 
develops invasive PDA and naturally mimics the histopathological and molecular 
features of human PDA development.20  Our KPC mice are fully backcrossed to a 
C57BL/6 background.  The KPC mice express dominant negative activating point 
mutation in the proto-oncogene KRAS and inactivating mutation in the tumor 
suppressor gene Trp53, the two hallmark genetic alterations in human PDA.20  
The KPC mice will develop tissue specific pancreatic cancer via the Cre-lox 
system, where mutant KRAS is expressed under the control of pancreatic 
specific promoter, Pdx1 (Figure 1.2).20  The KPC mice will exhibit a stepwise 
progression to PDA via multiples states of premalignant lesions resembling 
human PDA by genetic instability and histology.20 
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Figure 1.2          
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Figure 1.2 KPC transgenic mouse model mimics human pancreatic cancer  
(A) Expression of KRASG12D allele after PDX-1 Cre-mediated excision-
recombination of LSL- KRASG12Dallele. 
(B) Representative H&E images of premalignant PanIN progression to PDA.  
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miRNAs present a new and promising therapeutic platform for cancer and 
many other diseases.  The first miRNA lin-4 was discovered in C. elegans in 
1993 and the first mammalian miRNA let-7 was discovered 7 years later.21  Since 
then thousands of miRNAs have been discovered in humans alone and are being 
investigated as potential cancer intervention and therapeutic strategies.  miRNAs 
are short non-coding RNAs (ncRNAs) that are 19-25 nucleotides in length that 
post-transcriptionally regulate gene expression by binding to complementary 
target mRNAs resulting in their translational inhibition and/or degradation.21,22  
miRNA genes are located in intronic regions of the genome and once transcribed 
by RNA polymerase II, they are cleaved and processed in the nucleus by 
DROSHA to produce 60-70 nucleotide long precursor miRNAs (pre-miRNAs).23  
Pre-miRNAs are subsequently exported to the cytoplasm by exportin 5 where 
further processing occurs by DICER1 to produce a double-stranded mature 
miRNA.23  The single guide strand of the mature miRNA is loaded into the RNA-
induced silencing complex (RISC) containing DICER and Argonaute proteins.23  
The guide strand directs the RISC to achieve translational repression or mRNA 
decay via degree of complimentary sequence binding to the target mRNA.22  
Perfect complimentary binding to the 3’-UTR of target transcripts leads to mRNA 
cleavage and degradation, while imperfect binding (most cases in mammals) 
results in translational blockage.22  The 3’-UTR of mRNAs contain regions 
complimentary to many miRNAs, therefore a single miRNA may target several 
transcripts while a single transcript may be targeted by many miRNAs.24  Due to 
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this mechanism of inhibition, miRNAs are powerful regulators that have the ability 
to modulate multiple targets in multiple pathways.  
miRNAs have been shown to play important regulatory roles in the biology 
of PDA.  Both transformed tumor epithelial cells and stromal cell populations are 
regulated by miRNAs whose levels are dysregulated by tumorigenesis.  In 
pancreatic cancer cells, mutant KRAS  activation alters downstream miRNA 
expression such as those of miR-21, miR-31, miR-155, and miR-221.22,25  
Conversely, several miRNAs also directly regulate KRAS expression and can 
therefore act as tumor-suppressors.26  miR-30b, miR-30c, miR-181a, miR-
193b/365a, miR-613, and miR-134 all regulate KRAS  in various models of 
cancer, while let-7 family, miR-126, miR-96, miR-143, and miR-217 modulate 
KRAS expression specifically in PDA.5,26–28  miRNAs are also potent regulators of 
many cell populations in the stromal compartment, which is critical to PDA 
maintenance and propagation.  miR-155 secreted by pancreatic cancer cells 
converts normal fibroblasts to CAFs29,  while miR-21 modulates the migration 
and invasion of PSCs.30  miR-221 targets phosphatase and tensin homolog 
(PTEN) and tissue inhibitor of metalloproteinases-2 (TIMP-2) which increases the 
proliferative, migratory, and invasive capacity of CAFs.22,30  Signaling pathways 
of TGFβ, a key inflammatory cytokine that activates quiescent PSCs and 
fibroblasts to increase desmoplasia, is modulated by miR-34b, miR-483-3p, and 
miR-21 which inhibits SMAD3, SMAD4, and SMAD7 respectively.31–34  
Additionally, TGFβ1 stimulation leads to decreased expression of miR-29 in 
activated PSCs and CAFs, which results in increased ECM deposition furthering 
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fibrosis, an effect that is reversed with ectopic expression of miR-29.35  These 
data indicate how miRNAs are key regulators of multiple components of PDA.  
Such findings also suggest that miRNAs may be utilized to delay or halt early 
premalignant PanIN progression by targeting initiating driver mutation KRAS and 
the early TME.  Although many studies have examined the roles of miRNAs in 
established PDA, few studies have investigated miRNA regulation in early PDA 
development that may be targeted for PDA prevention and early interception.   
 
 
Table 1.1 miRNA therapeutics in clinical trials for various diseases  
 miR-16 mimic is currently being tested for non-small cell lung cancer and miR-34 
mimic is being tested for multiple solid tumors.  miRNAs for the treatment of PDA 
have yet to advance to clinical trials, an area that warrants further research.  
Table from Rupaimoole et al.21     
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The poor prognosis and high lethality of PDA is due to late detection of the 
disease.  More than 80% of patients present with late stage metastatic cancer at 
the time of diagnosis1, hence there is a great need for early detection methods.  
Recent studies have shown that profiles of circulating cell-free miRNAs in the 
peripheral blood of cancer patients have provided specific sets of miRNAs that 
are indicative of certain cancers.36–38  Not only are circulating miRNAs diagnostic 
biomarkers of disease, but they are also predictors of patient response to 
chemotherapies and likelihood of cancer recurrence, hence the levels of 
circulating miRNAs are sensitive to specific physiological stresses and 
phenomenon.39–42  Additionally, the non-invasive isolation of circulating miRNAs 
from a simple blood draw along with its stability in harsh conditions (freeze-
thawing, RNase digestion, wide pH range) confers feasibility to utilizing 
circulating miRNAs for cancer screening in the clinic.40,43  The stability of 
circulating miRNAs is achieved by its secretion in exosomes and microvesicles, 
which are currently also being profiled to assess their potential in enhancing 
circulating miRNA biomarker specificity.44  Utilizing the developmental KPC 
mouse model, we aim to build a developmental profile of circulating serum 
miRNAs in which alterations in circulating miRNA levels as compared to the 
levels of WT C57BL/6 mice may be indicative of the presence of low grade 
PanINs and initiation of early PDA disease progression.  Such studies will 
generate circulating miRNA signatures that can be feasibly utilized in the clinic 
for early PDA screening.  
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; and Pdx-1-Cre strains on 
a mixed C57BL/6 background, were gifted from Dr. David Tuveson (Cold Spring 
Harbor Laboratory, Cold Spring, NY).  These mice were backcrossed to the 
C57BL/6 genetic background for 12 generations and interbred to obtain KC and 
KPC mice.  All animals were kept in pathogen-free conditions and treated in 
accordance with Institutional Animal Care and Use Committee of the Johns 
Hopkins University and American Association of Laboratory Animal Care 
approved guidelines. 
Laser Capture Microdissection (LCM)   
Pancreata were isolated from aged KPC (4-20 weeks) or WT C57BL/6 mice and 
frozen in Tissue-Tek OCT (Sakura Finetek USA).  Guide slides were sectioned 
and stained with H&E by the Johns Hopkins University Oncology Tissue 
Services.  Guide slides containing various grades of PanINs were identified by a 
pathologist (R.A. Anders).  10, 10um frozen sections adjacent to guide sections 
were mounted on membrane slides (Zeiss) and stained with Cresyl Violet 
(Ambion).  Normal, low grade PanIN1, high grade PanIN2/3, and PDA tissue 
were microdissected using LCM (Leica LMD7000). 
miRNA Profiling Using miRNA Microarray  
RNA was extracted from LCM samples using RNAqueous™-Micro Total RNA 
Isolation Kit  (Thermo Fisher Scientific), quantified with NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific), and converted to cDNA using 
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TaqMan™ MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific) and 
Megaplex™ RT Primers Rodent Pool A and B (Thermo Fisher Scientific).  cDNA 
was preamplified 18 cycles using TaqMan™ PreAmp Master Mix (Thermo Fisher 
Scientific) and Megaplex™ PreAmp Primers Rodent Pool A and B (Thermo 
Fisher Scientific).  miRNA microarray was performed by the Johns Hopkins 
School of Medicine Genetic Resources Core Facility using TaqMan® 
OpenArray® Rodent MicroRNA Panel (Thermo Fisher Scientific) and TaqMan® 
OpenArray® Real-Time PCR Master Mix (Thermo Fisher Scientific).  All Ct 
values were normalized to endogenous levels of U6 snRNA.  Fold changes were 
quantified utilizing the ∆∆Ct method in which all PanIN groups were normalized 
to the normal group (normal ducts isolated from WT C57BL/6 mice). 
Quantitative RT-PCR (qPCR) of Top miRNA Candidates 
RNA was extracted from LCM samples or primary cell lines using RNAqueous™-
Micro Total RNA Isolation Kit  (Thermo Fisher Scientific), quantified with 
NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific), and converted to 
cDNA using TaqMan™ MicroRNA Reverse Transcription Kit (Thermo Fisher 
Scientific) with Taqman miRNA RT Assays (Thermo Fisher Scientific).  cDNA 
was preamplified 12 cycles using TaqMan™ PreAmp Master Mix (Thermo Fisher 
Scientific) and Taqman miRNA TM Assays (Thermo Fisher Scientific).  qPCR 
was performed using Taqman Universal Master Mix II (Thermo Fisher Scientific) 
on the StepOnePlus Real-Time PCR System (Life Technologies) and analyzed 
by ExpressionSuite Software (Thermo Fisher Scientific).  All Ct values were 
normalized to endogenous levels of U6 snRNA.  Fold changes were quantified 
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utilizing the ∆∆Ct method in which all PanIN groups, KPC tumor cells, and KPC 
CAFs were normalized to normal ducts isolated from WT C57BL/6 mice, WT 
pancreatic epithelial cells, or PNAFs respectively.  
Primary Cell Lines and Cell Culture 
Primary KPC tumor epithelial cell line, KPC CAF, and C57BL/6 pancreatic normal 
associated fibroblasts (PNAF) were gifted from Dr. Lei Zheng.  We performed 
fluorescent activated cell sorting (FACS) to further purify and enrich for each cell 
line.  KPC tumor cells were surface stained and sorted using anti-CD326 
(EpCAM)-FITC (eBioscience).  KPC CAFs were stained with primary antibody 
anti-FAP (Abcam) and secondary antibody Brilliant Violet 421 Donkey anti-rabbit 
IgG (BioLegend).  PNAFs were stained with anti-PDGFRα-APC (Biolegend).  All 
cell lines were dissociated with Cell Dissociation Buffer, enzyme free (Thermo 
Fisher Scientific), washed twice with sterile sorting buffer (PBS with 2% FBS), 
stained with primary antibody for 1 hour at 4 degrees in the dark, washed twice 
with sorting buffer, stained with secondary antibody for 30 minutes at 4 degrees 
in the dark, washed twice with sorting buffer, and then sorted using FACSAria 
Fusion SORP cell sorter (Becton Dickinson) by the Sidney Kimmel 
Comprehensive Cancer Center Flow Cytometry Core.  KPC tumor cells were 
sequenced to ensure that they have the appropriate KRAS and Trp53 mutations.  
KPC Tumor cells, KPC CAFs, and PNAFs were maintained in RPMI 1640 (Life 
Technologies) supplemented with 10% FBS (Gemini Bio-products), 1 mM sodium 
pyruvate (Sigma), 2 mM L-glutamine (Life Technologies), 1% nonessential amino 
acids (Life Technologies), penicillin (50 U/ml)/streptomycin (50 µg/ml) (Life 
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Technologies), and 0.2 U/ml human insulin (NovoLog) in a humidified incubator 
(37 degrees, 5% CO2).  C57BL/6 Mouse Primary Pancreatic Epithelial Cells (WT 
epithelial cells) were purchased from CellBiologics.  WT epithelial cells were 
maintained in Complete Epithelial Cell Medium with Kit (CellBiologics). 
Western Analysis of Phenotypic Markers  
Cells were trypsinized then lysed with RIPA buffer (Thermo Fisher Scientific) 
supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (Thermo 
Fisher Scientific).  Protein was quantified using Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific) according to the manufacturer’s instructions.  For 
Western Blotting, SDS PAGE was performed using the BioRad gel 
electrophoresis system.  Protein lysate samples were mixed with XT Reducing 
Agent (BioRad) and XT Sample Buffer (BioRad), run on 4-12% bis-tris Criterion 
XT gels (BioRad) at 150V, and transferred to nitrocellulose membrane (GE 
Healthcare).  Membranes were blocked using Odyssey Blocking Buffer, TBS (LI-
COR) for 1 hour at room temperature or overnight at 4 degrees with gentle 
shaking.  Primary antibodies anti-Vimentin (Abcam), anti-E-cadherin (Abcam), 
anti-α-smooth muscle actin (α-SMA) (Abcam), and anti-FAP (Abcam) were 
stained with secondary antibody IRDye® 800CW Donkey anti-Rabbit IgG (H + L) 
(LI-COR).  Endogenous control primary antibody anti-β-Actin (Abcam) was 
stained with secondary antibody IRDye® 680RD Donkey anti-Chicken IgG (H + 
L) (LI-COR).  Membranes were stained with primary antibodies diluted in 
Odyssey Blocking Buffer+0.2% Tween20 for 2 hours at room temperature with 
gentle shaking, washed 3 times with TBST (TBS with 0.1% Tween20), stained 
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with secondary antibodies diluted in Odyssey Blocking Buffer+0.2% Tween20 for 
1 hour at room temperature with gentle shaking in the dark, washed 3 times with 
TBST, then visualized with an Odyssey Infrared Imaging System scanner (LI-
COR).  Signal intensities were measured using FIJI software (ImageJ).45 
Proliferation, Invasion, and Migration Assays 
Cell Counting Kit-8 (CCK8) (Dojindo Molecular Technologies) was used for 
proliferation assays for all cell lines.  Cells were seeded on 96 well plates and 
after a 90 minute incubation with CCK8 solution in a humidified incubator (37 
degrees, 5% CO2) the absorbance was measured at 450nm.  This procedure 
was repeated every 24 hours starting on day 0 to day 4.  Invasion and migration 
assays were performed using Cultrex 96 Well BME Cell Invasion Assay kit 
(Trevigen) according to the manufacturer’s instructions.  The transwells were 
coated overnight with 1X basal membrane extract (BME) for invasion assays, 
while no BME coating was performed for migration assays.  For both assays, 
cells were serum-starved for 24 hours before plating.  Invasion and/or migration 
was measured 48 hours after plating cells using CCK8.  Scratch assay or wound 
healing assay to quantify migratory capacities was performed by seeding 24 well 
plates at high density to produce immediate confluency.  Once confluent, wells 
were scratched with a p200 pipet tip to produce a clear vertical partition and 
images were taken at 20X magnification using an Eos Rebel T2i camera (Canon) 
attached to a phase-contrast microscope.  After a 24-48 hour incubation 
(depending on cell line used) in a humidified incubator, another image was taken 
and migration was measured by quantifying the percent partition closure relative 
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to the 0 hour time point.  Area of partition at each time point was quantified using 
FIJI software (ImageJ). 
miRNA Fluorescence In Situ Hybridization (miR-FISH) 
In situ  detection of miR-21, miR-224 and U6 snRNA was performed using 
miRCURY LNA microRNA ISH Optimization Kit (Exiqon) as per the 
manufacturer’s instruction with modifications for frozen tissue sections.  H&E 
slides of aged KPC pancreata prepared by the Johns Hopkins University 
Oncology Tissue Services were examined by a pathologist (R.A. Anders) and 
PanINs of various grades were identified.  Subsequent 10 um frozen sections 
from histologically analyzed pancreata were fixed in 10% neutral buffered 
formalin overnight at room temperature.  All washes were done with DEPC-PBS.  
Proteinase K (20ug/ml) digestion was carried out in an ACD HybEZ hybridization 
oven at 38 degrees for 15 min.  Two 3 min washes with 3% hydrogen peroxide 
solution in DEPC-PBS was used to block endogenous peroxidases.  All locked-
nucleic acid (LNA) miRNA probes are double digoxigenin (DIG) labeled on the 5’ 
and 3’ ends, except for LNA-U6 which is DIG labeled only on the 5’ end.  
Hybridization with each LNA miRNA probe was performed at specific optimal 
temperatures.  LNA-miR-21 (TCAACATCAGTCTGATAAGCTA, 40nM) was 
hybridized at 54 degrees, LNA-miR-224 (AACGGAACCACTAGTGACTT, 40nM) 
was hybridized at 52.5 degrees, LNA-miR-Scramble 
(GTGTAACACGTCTATACGCCCA, 40nM) was hybridized at 54 degrees, and 
LNA-U6 (CACGAATTTGCGTGTCATCCTT, 1 nM) was hybridized at 54 degrees.  
All LNA probes were hybridized for 1 hour in a humidified hybridization oven.  
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After decreasing concentrations of 5 min SSC washes at probe hybridization 
temperatures, tissue sections were blocked for 15 min at room temperature in a 
humidified chamber using 5X In Situ  Hybridization (ISH) Blocking Solution 
(Vector Laboratories), diluted with sterile water to 1X working concentration.  
Sections were stained with primary antibody HRP-labeled anti-DIG (Gallus 
Immunotech) diluted in blocking solution for 60 min at room temperature in a 
humidified chamber.  TSA Plus Fluorescein (Perkin Elmer) detection substrate 
was applied to sections two times 5 min each in the dark in order to produce an 
amplified fluorescent signal.  Sections were then stained with nuclear dye 
Hoechst (Thermo Fisher Scientific) for 15 min in the dark.  Slides were mounted 
with Prolong Diamond Antifade Mountant (Thermo Fisher Scientific) and cured 
overnight in the dark with proper ventilation.  Slides were imaged the next day on 
Eclipse E800 fluorescence microscope (Nikon) at 20X magnification using the 
DAPI filter to capture nuclear staining and the FITC filter to capture miRNA 
staining.  In situ  miRNA expression was quantified by FITC intensity/nuclei using 
FIJI software (ImageJ).   
Lentiviral Stable Transduction of Primary Cell Lines with miRNA Mimics 
and Inhibitors  
All miRNA lentiviral particles were purchased from GeneCopoeia.  The 
GeneCopoeia third generation self-inactivating HIV-based lentiviral vector system 
meet Biosafety Level 2 (BSL-2) requirements based on the criteria outlined by 
the Centers for Disease Control.  Transduction of primary cell lines were 
performed according to the manufacturer’s protocol.  Viral suspension contained 
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8µg/ml of Polybrene (Sigma) and 10µl of lentivirus diluted in complete media 
appropriate for each cell line to be transduced.  Plates containing cells and viral 
suspension were placed in 4 degrees for 1.5 hours prior to overnight incubation 
in a humidified incubator (37 degrees, 5% CO2) to increase transduction 
efficiency.  Successfully transduced cells were selected via antibiotic selection 
using either 4µg/ml puromycin (Sigma) or 400µg/ml hygromycin B (Thermo 
Fisher Scientific).  Transduced cells after selection were viewed at 20X 
magnification under Eclipse TE200 inverted fluorescence microscope (Nikon) to 
assess transduction efficiency.  Cells were FACS sorted by eGFP or mCherry 
expression using FACSAria Fusion SORP cell sorter (Becton Dickinson) by the 
Sidney Kimmel Comprehensive Cancer Center Flow Cytometry Core to further 
enrich for successfully transduced cells.  
Isolation and Preparation of Serum miRNA for Circulating miRNA Profile 
Whole blood was isolated via cardiac puncture of the right atrium using a 26 
gauge subcutaneous needle (Becton Dickinson) immediately after aged KPC 
mice were euthanized.  After whole blood extraction, the pancreas was isolated 
and formalin fixed.  Whole blood was allowed to coagulate at room temperature 
for a minimum of 30 minutes and a maximum of 2 hours before spinning at 2,000 
g’s for 25 min at 4 degrees.  Serum was isolated and kept at -80 degrees until 
further processing.  H&E slides of pancreata (prepared by the Johns Hopkins 
University Oncology Tissue Services) of aged KPC mice in which serum was 
isolated from, were graded by a pathologist (R.A. Anders) based on the highest 
PanIN stage (or PDA) present.  Samples were grouped based on graded 
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biological groups normal.  Serum samples were thawed and spun at 16,000 g’s 
for 10 min at 4 degrees to remove cryoprecipitates.  C. elegans miR-39 mimic 
(Ambion) was spiked into 200ul of serum before total RNA extraction using 
miRNeasy Serum/Plasma Kit (Qiagen).  RNA concentrations were quantified with 
NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific).  Subsequent 
cDNA generation, preamplification, and serum miRNA microarray profiling was 
performed as described above for in-tissue miRNA microarray profiling.  
Statistical Analysis  
Statistical analysis was performed using GraphPad Prism v7.0b (GraphPad 
Software).  The data are presented as the means ±SEM.  Comparisons between 
groups were made using two-tailed unpaired Student t tests and one-way or two-














Comprehensive profile of miRNA expression in early PDA development in 
KPC mice  
While miRNA profiling has been performed for established PDA and 
models of late stage metastases, very few studies have constructed a 
comprehensive profile of key dysregulated miRNAs in early PDA development 
and progression.  Our profiling is performed using KPC mice, an endogenous 
model of PDA in which disease progression recapitulates human PDA initiation 
and development via expression of driver mutation KRASG12D  and loss-of-
function tumor suppressor Trp53  in pancreatic epithelial cells.  These mice 
develop increasing grades of premalignant PanINs before invasive PDA.  To 
construct our developmental miRNA profile, we isolated varying grades of 
PanINs from sections of aged KPC pancreata and performed miRNA microarray 
analysis quantifying the levels of 750 know murine miRNAs.   
To narrow down this extensive list to a few key miRNA candidates for 
further investigation, we employed specific selection criteria that all key 
candidates must meet.  First, we chose miRNAs that have low Ct values, 
indicating that they are strongly expressed.  Secondly, candidate miRNAs must 
have high ∆Rq values, indicating that there are large fold changes either 
increasing or decreasing over PanIN development.  Thirdly, we chose miRNAs 
who’s fold changes are significantly changing (P-value ≤ 0.05) between 
developmental PanIN groups, and lastly, our key miRNAs have either putative or 
proven roles in cancer promoting pathways.  Our top 14 miRNA candidates 
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selected from our initial screen are miR-21, miR-16, miR-224, miR-19b, miR-
106b, miR-29a, miR-20a, miR-28, miR-142-3p, miR-15b, miR-301b, miR-222, 
miR-221, and miR-216b.  The expression levels of all candidate miRNAs were 
validated by in-house qPCR (Figure 1.3) and exhibited the same trends and fold 
changes produced by the initial microarray screen.  Table 1.2  summarizes the 
fold changes over PanIN development and PDA of our top 14 miRNA candidates.  
Dysregulation of key miRNAs occur as early as low-grade PanIN1 and persist 
consistently to PDA.  Expression levels of well-characterized onco-miR-21 are 
increased by 55-fold in PanIN1 lesions and 333-fold in PDA as compared to the 





























                   
Figure 1.3 Expression of top 14 miRNA candidates in early PDA 
development.  Expression levels were quantified utilizing the ∆∆Ct method in 
which all Ct values were first normalized to endogenous control U6 snRNA and 
low-grade PanIN1 (P1), high-grade PanIN2/3 (P2/3), and PDA groups were 
normalized to the normal group (normal ducts isolated from WT C57BL/6 mice) 
to generate all fold changes.  Error bars represent average ± SE.  The hsa prefix 
denotes miRNAs that are found in both mice and humans due to sequence 











Table 1.2         
                   
Fold changes of the top 14 dysregulated miRNAs over early PDA 
development.  Quantified fold changes of miRNA expression, either increasing 
or decreasing, over developmental groups normalized to the expression levels in 
normal ducts of WT C56BL/6 mice.  
 
Establishment of primary cell lines of the TME for in vitro functional studies 
 The PDA TME is very dynamic, composed of many cellular populations 
and sub-cellular constituents that all serve to propel early progression of the 
disease.  PDA predominantly consists of tumor epithelial cells and recruited 
activated fibroblasts that comprise the dense stromal compartment of the tumor.  
To study the mechanistic regulation of the key miRNAs derived from our screen 
in early PanIN lesions and TME development, we established primary cell lines 
derived from primary KPC tumors and WT C57BL/6 pancreata for in vitro 
miRNA Normal P1 P2/3 PDA
hsa-miR-21 1 55 27 333
hsa-miR-16 1 7 7 148
hsa-miR-224 1 6 8 98
hsa-miR-19b 1 8 4 75
hsa-miR-106b 1 4 2 37
hsa-miR-29a 1 4 3 31
hsa-miR-20a 1 6 4 68
hsa-miR-28 1 6 4.2 36
hsa-miR-142-3p 1 5 7 50
hsa-miR-15b 1 4 4 39
mmu-miR-301b 1 5 4 111
hsa-miR-222 1 2 3 26
hsa-miR-221 1 3 3 42
miRNA Normal P1 P2/3 PDA




functional studies.  We established primary KPC CAFs, which are major 
components of the desmoplastic stroma characteristic of PDA.  Additionally, 
primary KPC tumor epithelial cells were isolated in order to study the miRNA-
mediated signaling mechanisms between tumor cells and CAFs in the TME.  The 
WT counterparts for these two cell lines were derived as well for comparison of 
transformed and activated phenotypes.  Normal pancreatic associated fibroblasts 
(PNAFs), the resident fibroblasts of the pancreas, were isolated from WT 
C57BL/6 mice.  Lastly, normal pancreatic epithelial cells were purchased from 
Cell Biologics.   
Following tissue dissociation and serial trypsin digestions, we employed 
FACs to further enrich for each cell line.  To isolate a pure population of PNAFs, 
we utilized platelet-derived growth factor receptor, alpha (PDGFRα) as a marker 
for cell sorting since PDGFRα is a surface marker for stromal cells, especially 
fibroblasts, of mesenchymal origin.46  For the enrichment of CAFs, we sorted 
using fibroblast activation protein (FAP), which is selectively expressed on 
activated stromal fibroblasts of epithelial cancers.17  To increase the purity of 
KPC tumor epithelial cells, we stained and sorted using epithelial cell adhesion 
molecule (EpCAM), which is a surface glycoprotein exclusively expressed on 
epithelia and epithelial-derived tumors.47  Figure 1.4  displays the flow cytometric 
analysis of the markers used for the sorting of each primary cell line along with 
the morphology of each cell line after sorting.  The proper morphology 
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Figure 1.4 FACs sorting and morphology of primary cell lines of the TME. 
(A) Sorting of PNAFs isolated from WT C57BL/6 pancreas using PDGFRα.  
Classic spindle-shaped morphology of fibroblasts is observed post-sort. 
(B) Sorting of CAFs isolated from a KPC tumor using FAP.  Classic spindle-
shaped morphology of fibroblasts is observed post-sort. 
(C) WT C57BL/6 pancreatic epithelial cells from Cell Biologics exhibited classic 
cuboidal-shaped morphology. 
(D) Sorting of KPC tumor epithelial cells isolated from a KPC tumor using 
EpCAM.  Classic cuboidal-shaped morphology of epithelial cells is observed 
post-sort.   







Phenotypic validation of primary cell lines by Western analysis, 
proliferation, and migration assays  
While the expression of PDGFRα for CAFs and FAP for PNAFs were 
robust, the expression of EpCAM for KPC tumor cells was weakly detected 
(10.7%) while sorting, hence further phenotypic confirmation is required for the 
validation of established primary cell lines.  We quantified protein expression of 
phenotypic markers of each cell type via Western Blot analysis (Figure 1.5).  To 
distinguish between WT C57BL/6 pancreatic epithelial cells and KPC tumor 
epithelial cells, we compared the expression of epithelial markers vimentin and 
E-cadherin.  The significant upregulation of vimentin and downregulation of E-
cadherin in KPC tumor cells as compared to WT epithelial cells confirms the 
transformed and untransformed phenotype of the two primary cell lines.  To 
validate PNAFs and CAFs, we quantified the expression of α-smooth muscle 
actin (α-SMA) and FAP.  The increased expression of FAP and slight 
upregulation of α-SMA in CAFs confirms its activated state compared to PNAFs.  
A defining phenotype of fully transformed and activated cells is increased 
proliferative capacity.  Thus, we utilized proliferation as another measure of 
distinct phenotypes of our established primary cell lines.  The CCK8 proliferation 
assay takes advantage of the WST-8 compound, which produces a water-soluble 
formazan dye upon reduction in the presence of electron mediators, such as 
dehydrogenases, in viable cells.  The colorimetric detection of the formazan dye 
at 450nm directly correlates with cell viability.  Figure 1.6  shows that KPC CAFs 
and tumor cells have the highest absorbance at 450nm, and therefore, proliferate 
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more than their WT counterparts (PNAFs and WT epithelial cells respectively) 
over 3 days, in which proliferation was measured every 24 hours.             
Like proliferation, increased cell migration is another acquired 
characteristic of a transformed and activated phenotype.  Utilizing the scratch 
assay or wound-healing assay, we quantified how quickly our primary cell lines 
migrated to close a partition generated by a scratch made on a confluent cell 
surface.  Figure 1.7  shows that after 24 hours in culture, KPC tumor cells 
achieved 94% wound closure whereas WT pancreatic epithelial cells only 
achieved 24% wound closure, demonstrating the significantly increased 
migratory capacities of transformed KPC tumor cells.  Similarly, KPC CAFs 
achieved 100% wound closure after 24 hours as compared to PNAFs that only 
migrated to cover 74% of the partition, indicating that CAFs migrate more than 
PNAFs.  Cumulatively, the quantified differences in marker expression, cell 
proliferation, and migration confirm the phenotypes of our primary cell lines on a 
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Figure 1.5 Protein expression of specific markers validate primary cell line 
phenotypes. 
(A) Representative blots and quantified protein expression of tumor epithelial 
markers vimentin and E-cadherin in WT pancreatic epithelial cells and KPC 
tumor cells.    
(B) Representative blots and quantified protein expression for activated fibroblast 




Figure 1.6 KPC tumor cells and CAFs proliferate more than WT epithelial 
cells and PNAFs respectively. 
Cells were plated at time 0 and proliferation was measured using CCK8 every 24 





Figure 1.7  
 
                          
Figure 1.7 Migratory capacities are increased in transformed KPC tumor 
epithelial cells and activated CAFs.  
(A) Representative images of partitions for each cell line at 0 hours and 24 hours.  
Cells were seeded at high density to produce immediate confluency.  Wells were 
scratched to produce a clear partition at 0 hours.  The degree of wound closure 
was measured 24 hours later normalized to the 0 hour gap.  
(B) Quantified relative % wound closure by measuring surface area of partitions 





miR-21 expression is increased in KPC tumor cells while miR-224 
expression is increased in CAFs  
Once the primary cell lines of the TME have been isolated and 
phenotypically validated, we investigated the expression levels of the top 4 
dysregulated miRNA candidates over early PDA development in our primary cell 
lines.  The top 4 dysregulated miRNA candidates (miR-21, miR-16, miR-19b, and 
miR-224) were selected out of those that were validated in-house based on their 
largest increases in expression over early disease progression.  The top 4 
miRNAs were also selected due to their sequence homology to human miRNAs; 
all 4 miRNAs sequences are conserved between mice and humans, allowing for 
more optimal translational investigation in human models.  Figure 1.8  shows the 
relative fold changes in expression of miR-21, miR-16, miR-19b, and miR-224 in 
KPC tumor cells and KPC CAFs as compared to WT pancreatic epithelial cells 
and PNAFs respectively.  miR-21 expression is significantly increased by 7-fold 
specifically in KPC tumor cells as compared to WT epithelial cells, and miR-224 
expression is significantly increased by 10-fold specifically in KPC CAFs as 
compared to PNAFs.  This data demonstrates that the expression of each 
miRNA varies between specific cell populations in the TME.  Furthermore, the 
activation state of each cell type may regulate or be regulated by changes in 
miRNA expression.  Due to the cell-type specific increases of miR-21 and miR-
224 and their regulation of targets in cancer-promoting inflammatory pathways48 
and epithelial-mesenchymal transition49, we decided to further investigate the 
mechanistic role of these two miRNAs in regulating the functionalities of our 
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Figure 1.8 Expression of top 4 miRNAs in primary cell lines of PDA TME.      
Relative fold changes of all 4 miRNAs were quantified using the ∆∆Ct method in 
which all Ct values were first normalized to endogenous control U6 snRNA and 
KPC tumor and CAF groups were normalized to WT pancreatic epithelial cells 









miR-FISH analysis to quantify endogenous spatial-temporal expression of 
miR-21 and miR-224 throughout early PDA development  
We employed miRNA fluorescence in situ  hybridization (miR-FISH) to 
examine the endogenous expression of miR-21 and miR-224 in specific 
structures and/or cell populations in early TME progression to PDA.  miR-FISH 
allows the fluorescent visualization of miRNAs in sections of whole tissue.  The 
intensity of the fluorescent signal directly correlates to the amount of endogenous 
miRNA expression.  For the detection of miRNAs in cryosections of whole tissue, 
we used locked nucleic acid (LNA) probes that are complimentary in sequence 
and therefore hybridize to miRNAs of interest at specific hybridization 
temperatures.  LNA probes are modified bicyclic RNA nucleotides that exhibit 
increased thermal stability in a duplex state post-hybridization.50,51  Additionally, 
the chemical modification of LNA probes improves mismatch discrimination to 
increase target accuracy.51  Increased thermal stability of duplexes in 
combination with improved accuracy of high-affinity hybridizations, make LNA 
probes ideal for detecting short miRNA targets.50,51 
  Figure 1.9  shows a general schematic of how miR-FISH detects 
endogenous miRNA in sections of whole tissue along with representative images 
of positive and negative controls used to define our experiments.  Figure 1.10  
shows the increased spatial-temporal expression of miR-21 specifically 
concentrated in the ductal epithelial cells of PanIN lesions over PDA 
development.  The quantified fluorescent signal of miR-21 demonstrates that 
there is a 6-fold increase of miR-21 expression in PDA tissue as compared to the 
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expression in normal WT C57BL/6 ducts, a fold increase that correlates closely 
to the fold increase obtained from qPCR analysis of miR-21 expression in KPC 
tumor cells as compared to WT pancreatic epithelial cells.  Interestingly, miR-
FISH analysis of miR-224 shows that miR-224 expression is concentrated in the 
invading stromal compartment surrounding high grade PanIN2/3 lesions and 
persists to PDA (Figure 1.11).  The varying compartmental-specific expression of 
miR-224 in the early stroma mirrors the qPCR findings in primary cell lines in 
which miR-224 expression is specifically upregulated in KPC CAFs, which are 
recruited to the site of tumorigenesis, as compared to PNAFs.  Moreover, similar 
to miR-21, the quantified fluorescent signal of miR-224 produced by miR-FISH 
demonstrates that the 10-fold increase of miR-224 in the stroma surrounding 
high-grade lesions, correlates closely to the fold increase obtained from qPCR 
analysis of miR-224 expression in KPC CAFs as compared to PNAFs.  Our miR-
FISH data not only confirms our qPCR results obtained from analysis of TME cell 
lines, but also further informs us of the compartmental-specific expression of 
















Figure 1.9 miR-FISH detects endogenous miRNA in sections of whole 
tissue.               
(A) LNA probes labeled with plant hapten digoxigenin (DIG) will hybridize to 
complimentary target miRNA sequences in sections of whole mouse pancreas.  
Sections are then stained with an HRP-conjugated, anti-DIG antibody.  Upon 
application of the detection substrate (TSA-FITC), HRP will catalyze the 
deposition of FITC where the target miRNA is expressed.  The detection 
substrate amplifies the expression signal by the deposition of many FITC 
fluorophores proximal to the miRNA of interest.  Endogenous miRNA expression 
is visualized with high resolution by fluorescent microscopy.  
(B) Representative fluorescent images of sections of pancreas stained with either 
no probe, scramble-miRNA probe that doesn’t target any miRNA, or U6 positive 
control probe.  No fluorescent signal was observed with no probe or scramble-
miRNA probe staining, however strong and ubiquitous fluorescent signal was 














Figure 1.10 Increased spatial-temporal expression of miR-21 in the 
developing TME over PDA progression. 
(A) Representative fluorescent images of normal ducts, increasing grades of 
PanIN lesions, and PDA tissue stained with miR-21.  Expression of miR-21 is 
concentrated in ductal epithelial cells.  
(B) Quantified image analysis of miR-21 fluorescent signal.  Raw fluorescent 
signals were quantified by FITC intensity/nuclei.  PanIN1, PanIN2/3, and PDA 
raw signals were normalized to that of normal pancreatic ducts of WT C57BL/6 





















Figure 1.11 Increased spatial-temporal expression of miR-224 in the 
developing TME over PDA progression. 
(A) Representative fluorescent images of normal ducts, increasing grades of 
PanIN lesions, and PDA tissue stained with miR-224.  Expression of miR-224 is 
concentrated in stromal compartment surround high-grade PanIN2/3 and PDA.  
(B) Quantified image analysis of miR-224 fluorescent signal.  Raw fluorescent 
signals were quantified by FITC intensity/nuclei.  PanIN1, PanIN2/3, and PDA 
raw signals were normalized to that of normal pancreatic ducts of WT C57BL/6 
mice to generate relative signal intensities.  
(C) Tiled fluorescent images of the top, middle, and bottom of the invasive 
stroma surrounding PanIN2/3 lesions highlighting the stromal 




Lentiviral stable transduction of primary cell lines with miR-21 and miR-224 
inhibitors and mimics 
To investigate how miR-21 and miR-224 functionally regulate early PDA 
development, we stably transduced the primary cell lines of the TME with miRNA 
inhibitors and mimics to investigate miR-21’s and miR-224’s mechanistic roles in 
mediating early disease progression.  Since KPC tumor cells express more miR-
21 than WT pancreatic epithelial cells and KPC CAFs express more miR-224 
than PNAFs, we used lentiviral vectors to stably inhibit endogenous levels of 
miR-21 in KPC tumor cells and miR-224 in KPC CAFs.  The inhibition occurs 
through expression of miRNA inhibitors that bind to target miRNAs via sequence 
complementation to prevent the loading of target miRNAs onto the RISC 
complex.  Conversely, we transduced WT pancreatic epithelial cells and PNAFs 
to endogenously overexpress miR-21 and miR-224 respectively.  Figure 1.12  
shows the miRNA inhibitor construct used, hygromycin selection post-
transduction, and transduction efficiency achieved in KPC tumor cells and CAFs.  
Figure 1.13  shows the miRNA mimic construct used, puromycin selection post-
transduction, and transduction efficiency achieved in WT pancreatic epithelial 
cells and PNAFs.  We sorted by each transduced cell line’s fluorescent marker 
(mCherry or eGFP) to further enrich for stably transduced cells after antibiotic 
selection.  Table 1.3  summarizes the lentiviral vectors, target cell lines, 
fluorescent markers, and antibiotic selection used to generate specific stable 
functionalities for downstream in vitro assays.  Stable modulation of these 
miRNAs will allow us to assess whether altering endogenous miRNA levels can 
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produce specific gain or loss-of-function phenotypes.    
 
Figure 1.12 
   
 






Figure 1.12 Stable inhibition of miR-21 in KPC tumor cells and miR-224 in 
CAFs. 
(A) miRNA inhibitor construct for miR-21 and miR-224 
(B) Hygromycin selection of stably transduced cells achieved at day 6 and 
onward.  Non-transduced KPC tumor cells and CAFs did not survive past day 6.  
However, cells transduced with scramble and miRNA inhibitor constructs 
possess hygromycin resistance and remain viable beyond day 6 under selection 
pressure.   
(C) Transduction efficiency of KPC tumor cells post-hygromycin selection 
visualized by mCherry fluorescence.  Sorting further enriched for stably 
transduced KPC tumor cells evidenced by increased mCherry fluorescence.   
(D) Transduction efficiency of KPC CAFs post-hygromycin selection visualized by 
mCherry fluorescence.  Sorting maintained high population of stably transduced 










Table 1.13 Stable overexpression of miR-21 in WT pancreatic epithelial 
cells and miR-224 in PNAFs. 
(A) miRNA mimic construct for miR-21 and miR-224 
(B) Puromycin selection of stably transduced cells achieved at day 6 and 
onward.  Non-transduced WT epithelial cells and PNAFs did not survive past day 
6.  However, cells transduced with scramble and miRNA mimic constructs 
possess puromycin resistance and remain viable beyond day 6 under selection 
pressure.   
(C) Transduction efficiency of WT epithelial cells post-puromycin selection 
visualized by eGFP fluorescence.  Sorting further enriched for stably transduced 
WT epithelial cells evidenced by increased eGFP fluorescence.   
(D) Transduction efficiency of PNAFs post-puromycin selection visualized by 






Table 1.3  Summary of lentiviral stable transduction of primary cell lines.   
 
Expression of miR-21 in KPC tumor cells and miR-224 in KPC CAFs are 
reduced post-stable inhibition 
Degree of miRNA inhibition was measured by qPCR to assess whether 
endogenous expression of miR-21 in KPC tumor cells and miR-224 in CAFs was 
successfully reduced by stable transduction of miRNA inhibitor constructs.  
Figure 1.14  shows the expression of miR-21 and miR-224 post-transduction.  
Successful transduction of miRNA inhibitor constructs significantly reduced the 









       
Figure 1.14 Stable transduction of miRNA inhibitor constructs reduced 
expression of miR-21 and miR-224.  
Relative fold changes of miR-21 and miR-224 were quantified using the ∆∆Ct 
method in which all Ct values were first normalized to endogenous control U6 
snRNA and all experimental groups were normalized to non-transduced KPC 
tumor cells and CAFs respectively.  Error bars represent average ± SE.  
(A) Relative miR-21 expression in WT pancreatic epithelial cells (WT Ep) and 
KPC tumor cells transduced with either miR-scramble inhibitor (KPC T Scri) or 
miR-21 inhibitor (KPC T 21i) compared to expression in non-transduced KPC 
tumor cells. 
(B) Relative miR-224 expression in PNAFs and CAFs transduced with either 
miR-scramble inhibitor (KPC CAF Scri) or miR-224 inhibitor (KPC CAF 224i) 




Inhibition of miR-21 in KPC tumor cells decreased cell proliferation, 
migration, and invasion 
Because endogenous miR-21 expression was successfully reduced in 
KPC tumor cells post-stable transduction, we next investigated the subsequent 
functional changes as a result of miR-21 modulation.  We therefore measured 
the proliferative, migratory, and invasive capacities of transduced KPC tumor 
cells to assess whether these functional phenotypes characteristic of transformed 
and activated cells were altered (Figure 1.15).  Our data demonstrates that miR-
21 inhibition in KPC tumor cells reduced proliferation by 2-fold as compared to 
non-transduced KPC tumor cells.  Additionally, downregulation of miR-21 
expression in KPC tumor cells significantly reduced both migration and invasion 
to levels comparable to that of WT pancreatic epithelial cells.  These findings 
indicate miR-21 is a powerful mediator of cell proliferation, migration, and 
invasion and furthermore, that reduction of miR-21 levels in KPC tumor cells can 










Figure 1.15      
                        
          
Figure 1.15 Inhibition of miR-21 in KPC tumor cells decreased cell 
proliferation, migration, and invasion. 
(A) Proliferation assay of non-transduced KPC tumor cells, KPC tumor cells 
transduced with either miR-scramble inhibitor or miR-21 inhibitor, and media 
alone.  Cells were plated at time 0 and proliferation was measured using CCK8 
every 24 hours up to 96 hours. 
(B) Migration assay of WT pancreatic epithelial cells (WT Ep), non-transduced 
KPC tumor cells, and KPC tumor cells transduced with either miR-scramble 
inhibitor (KPC T Scri) or miR-21 inhibitor (KPC T 21i).  Cells were seeded in a 
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transwell without BME coating and migration was measured using CCK8 48 
hours later. 
(C) Invasion assay of WT Ep, non-transduced KPC tumor cells, KPC T Scri, and 
KPC T 21i.  Cells were seeded in a transwell with 1X BME coating and invasion 
was measured using CCK8 48 hours later.  
  
Overexpression of miR-224 in PNAFs increased their migratory capacity  
 Parallel to our investigation of the functional regulation of miR-21 inhibition 
in KPC tumor cells, we examined the functional effects of endogenous miR-224 
overexpression in PNAFs.  While additional experiments are currently underway 
to measure the effects of miR-224 overexpression on PNAF proliferation and 
invasion, we have shown that PNAF migration is significantly increased as a 
result of increased miR-224 levels (Figure 1.16).  The wound-healing assay, also 
known as scratch assay, demonstrated that, upon upregulation of miR-224 
expression, PNAFs increased their migratory capacity by 2-fold compared to 
non-transduced PNAFs to achieve 100% wound closure after 24 hours of 
migration.  This migratory ability is equal to that of KPC CAFs, indicating that 
miR-224 overexpression can confer activated functional phenotypes, such as 






Figure 1.16  
                         
                                  
Figure 1.16 Increased PNAF migration due to miR-224 overexpression.  
(A) Representative images of partitions for non-transduced PNAFs and PNAFs 
transduced with either empty backbone, miR-scramble mimic, or miR-224 mimic 
at 0 hours and 24 hours.  Confluent surfaces were scratched to produce a clear 
partition at 0 hours.  The degree of wound closure was measured 24 hours later 
normalized to the 0 hour gap.  
(B) Quantified relative % wound closure by measuring surface area of partitions 
at 0 and 24 hours. 
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Comprehensive profile of circulating miRNAs in the serum of KPC mice 
over early PDA development 
The poor prognosis of PDA is due to the late detection of the disease.    
There is a great need for early biomarkers that can be feasibly used in the clinic 
to identify individuals with premalignant PanIN lesions before the onset of 
invasive PDA so that these high-risk individuals may be eligible for curative 
procedures and therapies.  Specific cell-free circulating miRNA profiles have 
been shown to be indicators of cancer occurrence and are predictors of patient 
responses to radiation and chemotherapies.  Hence, we aim to develop a 
comprehensive profile of serum miRNAs that may serve as an early signature for 
the presence of PanIN lesions.  Additionally, with the establishment of our in-
tissue miRNA profile over early PDA progression, we investigated whether the 
key miRNAs that are dysregulated in the early TME are reflected in circulation.  
We assessed whether the levels of dysregulated serum miRNAs mirror those 
that are dysregulated in tissue, and can therefore be utilized as an accurate and 
accessible indicator of early disease.             
Utilizing our KPC mouse model, we isolated serum from aged KPC mice 
that possessed specific grades of PanIN lesions and PDA confirmed by histologic 
analysis.  Post-miRNA isolation, expression levels of 750 know murine miRNAs 
were quantified by the same miRNA microarray platform used to generate our 
comprehensive in-tissue profile.  Table 1.4  summarizes the top 18 dysregulated 
serum miRNAs over early PDA development derived from our screen.  All fold-
changes were quantified using the ∆∆Ct method in which all Ct values were first 
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normalized to endogenous control miR-16, a validated and commonly used 
internal control for circulating miRNA normalization.52–55  miR-16’s mature 
sequence is also perfectly conserved between mice and humans.52  Serum 
miRNA levels of PanIN1, PanIN2/3, and PDA groups were then normalized to 
levels obtained from the serum of normal WT C57BL/6 mice.  Comparing the top 
dysregulated miRNAs found in-tissue (Table 1.2) to the ones found in serum 
(Table 1.4), only miR-222 is the common miRNA produced from both screens to 
exhibit the largest increase in expression over early PDA progression.  miR-222 
increases up to 26-fold in-tissue and up to 2-fold in serum throughout early 
disease development.  Additionally, miR-222, miR-338-3p, miR-190, miR-155, 
and let-7f have increased expression in human PanINs leading to PDA as shown 
by Goggins’ group.56  Additional in-house validation of key dysregulated serum 













         
Table 1.4 Fold changes of top 18 dysregulated serum miRNAs over early 
PDA development. 









miRNA Normal PanIN1 PanIN2/3 PDA
mmu-miR-467e 1 21.504 44.55 149.354
hsa-miR-367 1 0.312 0.648 40.286
hsa-miR-338-3p 1 8.01 3.373 5.112 *
rno-miR-190b 1 13.462 46.877 4.707
mmu-miR-503 1 5.732 1.62 3.831
rno-miR-207 1 11.203 2.476 3.273
hsa-miR-190 1 2.778 22.681 3.266 *
mmu-miR-7b 1 5.32 7.23 3.162
hsa-miR-125a-5p 1 1.061 1.446 3.161
mmu-miR-155 1 1.733 188.821 2.941 *
mmu-miR-380-5p 1 3.453 7.576 2.45
mmu-miR-383 1 4.641 2.502 2.444
hsa-let-7f 1 21.992 27.353 2.403 *
mmu-miR-467a 1 1.721 5.803 2.209
hsa-miR-147b 1 0.45 2.026 2.138
hsa-miR-222 1 1.497 1.434 2.022 *
mmu-miR-298 1 0.234 2.902 2.002
mmu-miR-467c 1 2.472 2.411 1.928
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DISCUSSION 
miRNAs are vast and potent regulatory networks that control many 
signaling pathways and therefore many cell populations within the dynamic PDA 
TME.  Further mechanistic understanding of these regulatory networks will 
uncover new targets for therapeutic intervention and potential for improving 
current PDA therapies.  In this study, we constructed a comprehensive profile of 
miRNA expression throughout early PDA development and assessed whether 
key dysregulated miRNAs can functionally modulate specific cell populations 
within the PDA TME.  Utilizing the KPC mouse model that endogenously 
develops tissue specific PDA that recapitulates human disease progression, 
we’ve elucidated key dysregulated miRNAs whose levels of expression are 
altered in early PanIN lesions before the onset of invasive carcinoma.  
Expression levels of miR-21, miR-16, miR-224, and miR-19b are upregulated in 
early low-grade PanIN1 lesions and consistently increase to established PDA.  
This data demonstrates that dysregulation of specific miRNAs occurs even in the 
earliest premalignant lesions following activation of driver mutation KRAS which 
may contribute to early propagation of the disease.      
To investigate how these key miRNAs mechanistically regulate PDA 
progression, we established primary cell lines of the PDA TME for in vitro 
functional studies.  A hallmark of PDA is the dense stromal compartment that 
supports and propagates the tumor, therefore we aim to understand how 
components of this desmoplastic stroma can be modulated via miRNA 
mechanisms.  CAFs are major constituents of the fibrotic stroma, hence we 
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established a primary CAF cell line in addition to a tumor epithelial cell line 
derived from resected primary KPC tumors for our studies.  Normal pancreatic 
fibroblasts and normal pancreatic ductal epithelial cells from WT C57BL/6 mice 
were obtained for comparison of transformed and activated phenotypes.  After all 
primary cell lines were sorted to enrich for purity, we phenotypically validated 
each cell line by assessing cell morphology, quantifying expression of specific 
epithelial (vimentin and E-cadherin) and fibroblast (α-SMA and FAP) markers, 
and measuring their proliferative and migratory capacities.  Each cell lines’ 
transformed and activated states were successfully confirmed.  With these 4 
phenotypically validated primary cell lines of the PDA TME, we have established 
an effective in vitro model to examine microenvironment dynamics, specifically 
inter-cell signaling and regulation.  These cell lines can also be utilized for future 
in vivo experimentation in immunocompetent C57BL/6 mice of identical 
background.        
To examine how our key miRNAs are regulating cell types within the PDA 
TME, we first quantified the expression of miR-21, miR-16, miR-224, and miR-
19b in our established primary cell lines.  We discovered that miR-21 expression 
was specifically upregulated in KPC tumor cells and miR-224 expression was 
specifically upregulated in KPC CAFs compared to WT pancreatic epithelial cells 
and PNAFs respectively.  This demonstrates that specific cell populations of the 
PDA TME have differential abundance of unique miRNAs, suggesting that 
distinct cell types in the TME are subject to miRNA species-specific regulation.  
We decided to further investigate miR-21 and miR-224 in early PDA development 
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due to their KPC tumor cell- and CAF-specific dysregulation.  Upon stable 
lentiviral inhibition and overexpression of miR-21 and miR-224 in our primary cell 
lines, we found that endogenous inhibition of miR-21 reduced KPC tumor cell 
proliferation, migration, and invasion.  Moreover, the levels of migration and 
invasion achieved post-miR-21 inhibition in KPC tumor cells were comparable to 
that of WT pancreatic epithelial cells, demonstrating that miR-21 is a powerful 
mediator of EMT and its inhibition can revert transformed phenotypes to that of 
normal untransformed cells.  The endogenous overexpression of miR-224 in 
PNAFs significantly increased their migratory capacity similar to that of CAFs.  
This may be due to miR-224’s targeting and subsequent downregulation of Rho-
GTPase activating proteins ARHGAP9 and ARHGAP21 thereby increasing cell 
motility and migration via activation of the RhoA/ROCK pathway.57  Additional 
studies are underway to further investigate the functional consequences of miR-
21 and miR-224 modulation in these cell lines.  Concurrently, we are utilizing 
Nanostring to profile the transcriptome and proteome of the stably transduced 
cell lines to assess the gene targets and major signaling pathways that are 
regulated by miR-21 and miR-224. 
To examine the endogenous spatial-temporal expression of miR-21 and 
miR-224 in whole tissue over early PDA development, we performed miR-FISH 
on sections of aged KPC pancreata to observe miRNA specific distributions 
throughout early disease progression.  miR-FISH revealed that miR-21 is 
expressed at low levels in normal pancreata, but is highly expressed particularly 
in ductal epithelial cells of high grade PanINs and PDA in KPC pancreata.  
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Conversely, miR-224 is specifically expressed by the infiltrating stromal 
compartment surrounding advanced lesions.  Quantified fluorescent intensity 
data strongly correlates with relative expression data from qPCR of miR-21 and 
miR-224 in KPC tumor cells and CAFs respectively.  Collectively, the miR-FISH 
data demonstrates the compartmental-specific expression of miR-21 and miR-
224 in the early PDA TME.  
Our study also aimed to explore the potential of utilizing serum miRNA 
profiles as surrogate diagnostic molecular signatures for the presence of early 
stage PanINs.  Such diagnostic profiles will identify high-risk individuals prone to 
develop invasive PDA so that they may receive therapies early in disease 
development to improve prognosis.  Our serum miRNA profiling produced 18 key 
miRNAs in circulation that was increasing in expression over PDA development 
in KPC mice.  Five of which, miR-338-3p, miR-190, miR-155, let-7f, and miR-222, 
are also found to be increased in human PanIN lesions.56  Further validation 
needs to be performed for the top serum miRNA candidates.  Once validated, the 
serum miRNA profile needs to be assessed for its ability to accurately and 
sensitively detect specific grades of premalignancies in KPC mice.  Our data 
indicates that serum miRNAs can be promising diagnostic tools for early stage 
PDA screening in the clinic. 
miR-21 has been well-studied in many cancers and its oncogenic roles in 
tumorigenesis and the inflammatory TME have been well-characterized.48  
However, the role of miR-224 in CAFs has not been reported.  Our studies show 
for the first time that miR-224 expression is not only increased in CAFs, but also 
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specific to the stromal compartment of the early PDA TME in vivo and has the 
ability to increase motility of normal fibroblasts to that of activated CAFs.  Taken 
altogether these data show that CAFs recruited to the PDA TME have high 
expression of miR-224 which may contribute to the activation of proximal normal 
resting fibroblasts to exhibit activated phenotypes.  This mechanism of action 
may be mediated by the inflamed PDA TME and subsequent elevated activation 
of the NFkB pathway in CAFs,19,58 leading to increased NFkB transcription factor 
binding directly to the promoter region of miR-224 causing its overexpression.57  
Higher levels of miR-224, encapsulated in exosomes, may also be secreted into 
the PDA TME to increase migration of proximal normal fibroblasts in a paracrine 
fashion.   
In this study, we have shown miR-21 to be upregulated in transformed 
KPC tumor cells leading to their increased proliferation and EMT.  However, it 
has been reported that miR-21 is also overexpressed in CAFs, which increases 
TGFβ-mediated fibrosis via directly targeting SMAD7, an inhibitor of the TGFβ 
pathway.31,32  In fact, in vivo inhibition of miR-21 attenuated fibrosis in a mouse 
model of fibrotic lung disease31, a finding that is very promising for our efforts to 
employ miRNA-mediated interception of PDA development because the dense 
fibrotic stroma is an integral component of the TME that propels PDA.  
Additionally, miR-21 has been shown to skew tumoricidal pro-inflammatory M1 
macrophages to tumor-supportive anti-inflammatory M2 macrophages, or tumor-
associated macrophages (TAMs), once recruited to the TME.48  Therefore miR-
21 exerts its oncogenic effects on multiple cell populations in the developing 
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TME, providing strong rationale for inhibiting this miRNA in early disease 
progression.  
Utilizing our developmental KPC mouse model, we will administer miR-21 
and miR-224 inhibitors, either alone or in combination, to KPC mice 4-5 weeks of 
age in which pancreata will predominantly contain normal ducts and low-grade 
PanIN1 lesions.  After drug regimen, we will histologically analyze the degree of 
PanIN progression in KPC pancreata and assess whether early intervention with 
inhibitors that target these oncogenic miRNAs will slow disease progression.  We 
hope that by targeting miR-21 and miR-224 concurrently, we will mount a potent 
and multi-level attack on the early PDA TME to impede disease progression and 














CHAPTER TWO: Combination immunotherapy intercepts murine pancreatic 
cancer progression 
SUMMARY 
Immunotherapy agents that activate T cells are changing clinical 
treatments for solid metastatic malignancies.  Vaccines targeting viral oncogenes 
successfully prevent the development of hepatocellular and cervical cancers, 
carcinomas that result from tissue-specific viral infections.  We therefore tested 
the hypothesis that a vaccine targeting the oncogene that initiates pancreatic 
cancer (PDA) given in combination with immunotherapy agents that reprogram 
the earliest procarcinogenic inflammatory changes will slow or intercept PDA 
development.  The KRAS  oncogene is a driver mutation expressed in >90% of 
pancreatic intraepithelial neoplasms (PanINs) and an ideal candidate target for 
early vaccination against PDA.  However, even early PanINs have 
immunosuppressive microenvironments that highly express inhibitory immune 
checkpoint molecules like CTLA-4, and are well-infiltrated with 
immunosuppressive cell populations such as T regulatory cells (Tregs) that 
significantly dampen the efficacy of current immunotherapies.  
The overall goal of our study is to reprogram the immunosuppressive TME 
while specifically activating immunity against early premalignancies to prevent 
PDA development.  We previously reported that early dosing of 
KrasG12D/+;Trp53R172H/+;Pdx-1-Cre (KPC) mice, a spontaneous model of human 
PDA tumorigenesis, with the Treg depleting and inactivating agents 
cyclophosphamide (Cy) and PC61 antibody in combination with an attenuated 
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Listeria monocytogenes  vaccine expressing mutant KRASG12D (LM-Kras) can 
slow tumorigenesis in 40% of mice.  In this study, we aimed to improve the 
efficacy of this vaccine approach by specifically inhibiting the immunosuppressive 
effects of the CTLA-4 immune checkpoint on Tregs with a CTLA-4 blocking 
antibody to enhance activation of the immune system against early lesions.  
KPC mice at 4-5 weeks of age with low-grade PanIN1 lesions received 2 
doses of LM-Kras and Cy/PC61 and 8 doses of anti-CTLA-4 antibody.  Control 
mice received isotype antibody with LM-Kras and Cy/PC61 or no treatment.  At 
the end of the drug regimen in which KPC mice were 10-11 weeks of age, 
pancreata were histologically evaluated for various grades of PanINs or PDA 
tissue to assess degree of disease progression.  Mice that received triple 
treatment (LM-Kras, Cy/PC61, and anti-CTLA-4) had a significantly lower 
incidence of PanINs and PDA compared to controls.  Furthermore, they did not 
develop lesions beyond PanIN1, indicating that the combination therapy may halt 
PDA development at early stages.  
To investigate the immune profiles of mice receiving treatment, flow 
cytometry was performed on tumor-infiltrating lymphocytes (TILs) isolated from 
pancreata to assess abundance of Tregs, infiltration of effector and memory T 
cell populations, and expression of inhibitory immune checkpoint molecules.  
Mice that received triple combination therapy had decreased numbers of Tregs, 
decreased expression of specific immune checkpoints, increased activation of 
cytotoxic CD8+ T cells that produced more effector cytokines, increased memory 
T cells, and higher CD8+ T cell to Treg ratio in the microenvironment compared 
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to controls.  Additional mechanistic studies are underway to further characterize 
the immune changes in the microenvironment following treatment.  Collectively, 
our data demonstrates that our combination treatment successfully reprograms 
the early TME through several immune mechanisms to intercept PDA 





















The field of cancer immunoprevention has achieved significant progress in 
the last two decades with the implementation of prophylactic vaccines that target 
viral oncogenes to prevent the development of primary cancers that result from 
chronic viral infections.59  These “infectious tumors” account for 10-20% of all 
human tumors.60  The most successful examples of cancer-preventing 
prophylactic vaccines are ones that target hepatitis B virus (HBV) and human 
papillomavirus (HPV).60–62  Initially developed to prevent acute chronic hepatitis, 
the HBV vaccine produced the unexpected beneficial effect of dramatically 
reducing the incidence of post-hepatitis hepatocellular carcinoma.60,61  However, 
the original intent of developing the HPV vaccine was to prevent cervical cancer 
caused by persistent HPV infection, hence the HPV vaccine was the first “pure” 
implementation of human cancer immunoprevention.60  Although the efficacy of 
HPV vaccines in preventing cervical cancer has yet to be fully determined due to 
its recent worldwide distribution, the very promising results from ongoing clinical 
trials predict a near complete prevention of cancer occurrence.60  Since the 
majority of human cancers are not caused by viral infection, the next step and 
current goal in the field is to translate the successes of prophylactic vaccine 
development against infectious tumors to the development of immune-based 
strategies to prevent non-infectious tumors.63  
The successful immunoprevention of the remaining >80% of human 
cancers not induced by viral infection relies on strategic vaccine design.  
Selection of target antigen determines tumor-specific vaccine efficacy, degree of 
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immunologic response, and potential of associated toxicities.  An optimal antigen 
target should be an early alteration of a normal gene that is likely an initiator 
(driver) of tumorigenesis so that the immune response is directed toward a 
“causative” signal without which the developing tumor cannot survive.3,63  
Vaccination against such a target is likely to produce an immunologic response 
that is both efficacious and the least toxic, mounting a focused and concerted 
immune response to early neoplasms.63,64  There are major classifications of 
tumor antigens that are currently being utilized as targets for prophylactic vaccine 
efficacy studies.  Tumor specific antigens (TSAs) are exclusively expressed on 
tumor cells and not on any other cell, therefore these targets are unique to the 
tumor and are optimal candidates for vaccine-based immunotherapies due to 
their specificity.  TSAs are often mutated proteins such as KRAS, HER-2/neu, 
and EGFR.2,65–67  Tumor associated antigens (TAAs), however, are endogenous 
antigens present on both tumor and normal cells but are overexpressed 
specifically in transformed cells.  MUC1, Cancer-testis (CT) antigens, and ENO1 
are examples of TAAs currently under investigation.62,68–71  Specifically in PDA, 
mutant KRAS is an ideal TSA for early immune-mediated disease interception 
due to its mutated state conferring target specificity, role as a driver mutation of 
PDA tumorigenesis, high expression throughout premalignant progression (90% 
in PanIN1 lesions and 95% in PDA)2, and accessible location on the plasma 
membrane for immune recognition.  Hence for our vaccine studies, we have 
utilized a KRASG12D for targeted PDA intervention.   
Mutant KRAS not only transforms ductal epithelial cells, but it also 
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simultaneously establishes and propagates the early desmoplastic stroma to 
create an immunosuppressive, non-immunogenic TME.  The PDA TME contains 
many immunosuppressive immune populations that are either directly recruited 
to the site of tumorigenesis or become reprogrammed to exhibit 
immunosuppressive phenotypes once exposed to the abundant pro-tumorigenic 
signaling in the local TME (Figure 2.1).  The transformed tumor cells expressing 
mutant KRAS secrete IL-6, IL-8, and granulocyte macrophage colony stimulating 
factor (GM-CSF) that recruit Tregs and myeloid-derived suppressor cells 
(MDSCs) to the early TME.72–74  Tregs are a major immune inhibiting population 
that produces immunosuppressive cytokines TGFβ and IL-10.73  Additionally, 
Tregs express the immune checkpoint molecule cytotoxic T lymphocyte 
associated protein 4 (CTLA-4) that tethers co-stimulatory signals, thereby 
inhibiting CD4 and CD8 activation and expansion.72,73  MDSCs, upon TME 
infiltration, produce reactive oxygen species that result in T cell apoptosis.75  
They also deplete L-arginine, an essential amino acid necessary for T cell 
function.75  CCL2, CSF-1, and VEGF are also secreted by tumor cells to recruit 
circulating monocytes to the TME where they are locally induced by TGFβ and 
IL-10 to become tumor-associated macrophages (TAMs) that closely resemble 
anti-inflammatory M2 macrophages.76,77  In addition to the inhibitory immune 
checkpoint CTLA-4, the PDA TME is also rich in other checkpoint molecules 
such as PD-L1 and LAG-3.73  Collectively, the cellular pathways and signaling 
mechanisms that normally prevent auto-immunity are exploited by the tumor and 
TME to promote immune inactivation and tolerance, ultimately allowing the 
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developing tumor to evade immune recognition and eradication.  Therefore, 
combination immunotherapy must be employed to both activate the immune 
system against driver mutations and reprogram multiple immunosuppressive 




Figure 2.1 Genetic changes recruit and reprogram immune populations in 
the early PDA TME.  
Figure from Zheng et al.72  
 
The timing of immunotherapeutic administration determines disease 
prevention efficacy.  It has been shown that inactivation of mutant KRAS  only at 
the early PanIN stage in an inducible mouse model of endogenous PDA led to 
complete tissue recovery: lesion regression, metaplasia reversal, and stromal 
 73 
remodeling.3  While inactivation of mutant KRAS at later stages (during high-
grade PanINs) during did not achieve full tissue regression, but led to massive 
local cell death.  This finding not only further emphasizes the requisite role of 
mutant KRAS  activation in forming and maintaining the TME, but it demonstrates 
that mutant KRAS intervention needs to occur at early stages of PanIN 
development in order for complete reversal of premalignant lesion and stromal 
formation, before cells are in a state of oncogene addiction.3  This finding is also 
supported by our group in which only the early administration of LM-Kras vaccine 
in combination with Treg depleting and inactivating agents conferred survival 
benefit to KPC mice.  However, mice that received LM-Kras vaccine alone did 
not have increased overall survival or delayed PanIN progression despite early 
administration and significant peripheral mutant KRAS-specific CD8 T cell 
responses.78  These data demonstrate that the early vaccine-mediated targeting 
of mutant KRAS needs to be coupled with early adjuvant modulation of the 
immunosuppressive TME so that the primed and activated antigen-specific T 
cells can traffic to and infiltrate the TME, while remaining activated to recognize 
its antigenic target to achieve tumor cell killing.78,79  Our study aims to build upon 
the findings of Keenan et al. by adding immune checkpoint blockade to our 
combination immunotherapy to further reduce inhibitory TME signaling and 
enhance immunity against early PDA development. 
For our studies, we utilized recombinant live-attenuated intracellular 
bacterium Listeria monocytogenes  expressing KRASG12D (LM-Kras) as a vaccine 
to induce potent innate and adaptive immune responses against mutant 
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KRASG12D tumor antigen.  Upon vaccination, LM-Kras is actively phagocytosed 
by antigen-presenting cells (APCs) where KRASG12D is secreted into the cytosol 
and subsequently processed and presented through both class I and II antigen-
processing pathways, inducing specific CD4 and CD8 T cell immunity.80  The 
strain of Listeria used has a deletion of two virulence factors ActA (∆actA) and 
Internalin B (∆inlB) that significantly reduces its toxicity (>1000 fold reduction as 
compared to WT Listeria) while maintaining it immunopotency in vivo.81  ∆actA 
blocks cell-to-cell infection from adjacent phagocytic cells, while ∆inlB  prevents 
infection of nonphagocytic cells.81  Vaccinated mice produced durable effector 
and memory T cell responses without liver toxicity.81  In clinical trials, an LM 
vaccine expressing mesothelin safely induced mesothelin-specific T cell 
responses in patients with lung, ovarian, and pancreatic cancers.82  Listeria-
based vaccines are effective in delivering TSAs and TAAs to elicit potent 
antitumor immune responses. 
Inhibitory Tregs in the early TME are inactivated and depleted using a low 
dose of Cyclophosphamide (Cy), a chemotherapeutic DNA-alkylating agent83, in 
combination with PC61 monoclonal antibody.  Naturally occurring Tregs are a 
subset of CD4 T cells that play a critical role in the maintenance of self-
tolerance.84  However, in the context of cancer, their immunosuppressive 
functions facilitate tumor progression by preventing the activation of effector T 
cells in the TME.  Tregs specifically express Foxp3, a transcription factor that is 
essential for the development of their regulatory phenotype.85  Foxp3 produces 
TGFβ, an immunosuppressive cytokine that further expands Tregs, polarizes 
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TAMs/M2 macrophages, and increases stromal fibrosis to support the developing 
tumor.73,85  Additionally, Tregs induce in vitro and in vivo effector T cell apoptosis 
by sequestering IL-2 through the constitutive expression of high-affinity IL-2 
receptors, depriving the local environment of this key pro-inflammatory 
cytokine.86  The number of Tregs in the TME increases as premalignancies 
advance to PDA78 (Figure 2.2), and high frequency of tumor-infiltrated Tregs 
correlate with poor patient survival in many solid malignancies.85  Therefore, to 
reduce Tregs in the TME, we utilized a low dose of Cy, which selectively 
suppresses Tregs at low concentrations83,87, and PC61 antibody that binds to 




Figure 2.2 Increasing numbers of Foxp3+ Tregs in KPC premalignant 
lesions to PDA.   
Figure from Keenan et al.78 
 
 The third component in our combination immunotherapy is anti-CTLA-4 
immune checkpoint inhibitor.  CTLA-4 is a key negative regulator of T cell 
activation.  It is an inhibitory checkpoint molecule expressed on the surface of T 
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cells post-activation to attenuate excessive immune stimulation in order to 
preserve self-tolerance; therefore, CTLA-4 is critical for maintaining immune 
homeostasis.89  CTLA-4 has shared ligands with costimulatory receptor 
CD28.89,90  However, when expressed, CTLA-4 binds with higher affinity, and 
therefore outcompetes CD28 for the binding of their shared ligands B7.1 (CD80) 
and B7.2 (CD86) on APCs.89,90  CTLA-4’s tethering of the shared ligands 
prevents transmission of CD28’s costimulatory signal so the T cell remains 
inactivated in a state of anergy.89,90  Although conventional T cells will express 
CTLA-4 upon activation, Tregs highly express CTLA-4 constitutively which 
greatly contributes to their suppressive role in the TME.89,90  Due to this 
mechanism of inhibition, CTLA-4 compromises T cell survival, expansion, and 
recognition of target antigen, providing strong rationale for inhibiting this molecule 
to activate the immune system against early neoplasms.89  Administration of 
CTLA-4 inhibitor depletes Tregs to enhance antitumor efficacy in mouse models 
of melanoma.91,92  CLTA-4 blocking antibody mediates Treg depletion by binding 
to the receptor and triggering antibody-dependent cell-mediated cytotoxic 
(ADCC) lysis by nonclassical monocytes.93  The fully humanized monoclonal 
CTLA-4 blocking antibody, Ipilimumab, was approved by the FDA in 2011 for the 
treatment of metastatic melanoma, and while single agent therapy was effective 
in immuno-permissive cancers such as melanoma, it failed in patients with 
refractory, immunologically “cold” cancers such as PDA in which the 
immunosuppressive TME is a formidable barrier to immune infiltration.79,94,95  
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Therefore, multi-component combination therapy must be utilized to produce a 
well-infiltrated, immunogenic early PDA TME for disease interception.    
 






; and Pdx-1-Cre strains on 
a mixed C57BL/6 background, were gifted from Dr. David Tuveson (Cold Spring 
Harbor Laboratory, Cold Spring, NY).  These mice were backcrossed to the 
C57BL/6 genetic background for 12 generations and interbred to obtain KC and 
KPC mice.  All animals were kept in pathogen-free conditions and treated in 
accordance with Institutional Animal Care and Use Committee of the Johns 
Hopkins University and American Association of Laboratory Animal Care 
approved guidelines. 
Vaccine and Drug Treatments 
Vaccine and immunotherapeutic agents were administered to KPC mice 
according to the dosing scheme outlined in Figure 2.3.  LM-Kras (Aduro Biotech) 
5 x 105 colony-forming units in 0.2 mL phosphate-buffered saline was 
administered intravenously (IV).  Stock titers were determined for each batch of 
vaccine by dose titrations on brain heart infusion (BHI) agar plates.  PC61 (50 µg/ 
mouse)96 and cyclophosphamide (Cy) (100 mg/kg; Bristol- Myers Squibb) were 
administered by intraperitoneal injection (IP).  Anti-CTLA-4 (clone 9H10) or 
isotype antibody (both 100 µg/mouse; BioXcell) was also administered by IP. 
Histologic Analysis of PanIN Lesions 
 78 
At the end of the drug regimen, pancreata of KPC mice were formalin-fixed and 
paraffin-embedded, sectioned, and stained using routine H&E protocols by the 
Johns Hopkins University Oncology Tissue Services.  For the assessment of 
drug treatment effects, 2 slides from each pancreas spaced 400 µm apart were 
graded based on the highest PanIN stage (or PDA) present by a pathologist 
(R.A. Anders) blinded to the treatment group. 
Isolation of Tumor-Infiltrating Lymphocytes (TILs) 
Pancreata were excised immediately after KPC mice were euthanized and 
placed in IMDM media (Life Technologies) supplemented with 5% FBS (Gemini 
Bio-products), 1% L-glutamine (Life Technologies), penicillin (50 
U/ml)/streptomycin (50 µg/ml) (Life Technologies), and 0.09% 2-mercaptoethanol 
(Gibco).  Pancreata were weighed, diced into small 2-3 mm pieces, and 
dissociated using the Tumor Dissociation Kit mouse (Miltenyi) and gentleMACS 
Octo Dissociator (Miltenyi) according to the manufacturer’s protocols for soft and 
medium or tough tumors in the pancreata.  The heating functionality was always 
applied.  After tissue dissociation, cell suspensions were quenched with IMDM 
media, spun down for 10 minutes at 1700 rpm at 4 degrees, resuspended in 
IMDM, and mashed through a 70 µm strainer to produce a single cell 
suspension.  We performed a 40%:80% percoll (GE Healthcare) gradient to 
isolate lymphocytes from whole cell suspension.  Gradients were spun at 3500 
rpm at room temperature for 25 minutes.  Once the lymphocyte layer at the 
gradient interface was extracted, cells were quenched with IMDM, spun down, 
and counted.  Lymphocytes were stimulated overnight (17 hours) in a 37 degrees 
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humidified incubator (37 degrees, 5% CO2) using Dynabeads Mouse T-
Activator  CD3/CD28 magnetic beads (Gibco) per the manufacturer’s 
instructions.  Protein transport inhibitor GolgiPlug (BD Biosciences) was applied 
to lymphocytes during the last 5 hours of stimulation for the accumulation of 
intracellular cytokines.  Post-stimulation, CD3/CD28 magnetic beads were 
removed using DynaMag-15 magnet (Thermo Fisher Scientific).        
Cytokine Staining and Flow-Cytometry 
Lymphocytes were washed with PBS, stained with LIVE/DEAD Fixable Aqua 
(Life Technologies) for 30 minutes on ice in the dark, washed 2 times with PBS, 
Fc blocked with anti-mouse CD16/CD32 (BD Biosciences) for 15 minutes on ice, 
and stained for surface markers diluted in FACS buffer (PBS with 1% FBS and 
0.1% NaN3) for 30 minutes on ice in the dark.  Cells were washed 3 times with 
FACS buffer, fixed and permeabilized using the Foxp3 Transcription Factor 
Staining Buffer Set (eBioscience) for 30 minutes at 4 degrees in the dark, 
washed twice with permeabilization buffer (eBioscience), Fc blocked for 15 
minutes on ice, and stained for intracellular markers for 1 hour at 4 degrees. After 
3 washes with permeabilization buffer, cells were resuspended in FACS buffer 
and run on a Gallios flow cytometer (Beckman Coulter) after overnight storage at 
4 degrees in the dark.  Analysis was performed using FlowJo (Tree Star).  All 







Table 2.1 Flow Cytometry Antibodies 
 
Statistical Analysis  
Statistical analysis was performed using GraphPad Prism v7.0b (GraphPad 
Software).  The data are presented as the means ±SEM.  For the analysis of 
PanIN lesions, the Mann-Whitney test was used to compare ranks between 
treatment groups.  Comparisons between multiple groups were made using one-
way or two-way ANOVA.  For all analyses, P-values ≤  0.05 were considered 






Antibody Fluorochrome Clone Vendor
CD4 PerCP-Cyanine5.5 RM4-5 eBioscience
CD8 APC-Fire 750 53-6.7 BioLegend
CTLA-4 PE UC10-4F10-11 BD Biosciences
PD-1 PE-Cyanine7 J43 eBioscience
Lag3 Brilliant Blue 515 C9B7W BD Biosciences
Galectin-3 AF647 M3/38 BioLegend
Foxp3 AF700 FJK-16s eBioscience
IFNγ PerCP-Cyanine5.5 XMG1.2 eBioscience
TNF-α AF700 MP6-XT22 BD Biosciences
Granzyme B FITC NGZB eBioscience
CD44 Pacific Blue IM7 BioLegend
CD62L APC MEL-14 BD Biosciences
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RESULTS 
LM-Kras vaccine, Treg depleting agents, and CTLA-4 inhibition in 
combination intercepts PanIN progression 
 Utilizing our developmental KPC mouse model, we strove to improve upon 
what our group has previously shown that by early administration of driver 
mutation KRASG12D-targeting vaccine LM-Kras in combination with Treg depleting 
and inactivating agents Cy and PC61, we can successfully delay PDA 
progression at early premalignant stages by inducing KRASG12D-specific 
immunity and reprogramming the immunosuppressive TME.  We have 
supplemented this immunotherapy with anti-CTLA-4 checkpoint blockade to 
reduce the inhibitory effects exerted on the immune system by this molecule, 
while simultaneously further depleting Tregs in the developing TME.  We dosed 
KPC mice according to the timeline in Figure 2.3a.  After 6 weeks of drug 
treatment, when KPC mice were 10-11 weeks old, we performed gross 
pathological analysis of the PanINs present in the pancreata of various treatment 
groups to assess the physiological effects our combination immunotherapy has 
on PDA progression.  Our histology data (Figure 2.3b) revealed that KPC mice 
that had received triple treatment (LM-Kras, Cy/PC61, and anti-CTLA-4 antibody) 
developed significantly lower grades of PanIN lesions than all other groups.  
Furthermore, triple treatment mice did not develop lesions beyond low-grade 
PanIN1 indicating that triple combination immunotherapy was more effective at 
impeding PDA developing than what our group has previously achieved.  
Observing this promising physiological effect, we proceeded to investigate the 
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immune mechanisms that were being modulated by triple combination 
immunotherapy to halt PanIN progression.   
 
Figure 2.3 
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Figure 2.3 Triple combination immunotherapy delays PanIN development in 
KPC mice. 
(A) Dosing scheme of KPC mice.  4-5 week-old KPC mice, when normal or low-
grade PanIN1 lesions are predominantly present, are given Cy (100mg/kg) and 
PC61 antibody (50µg/mouse) IP one day before IV vaccination with LM-Kras (5 x 
105 cfu).  Two days after LM-Kras vaccination, three doses of anti-CTLA-4 
antibody (αCTLA4) were given three days apart, followed by two more doses of 
αCTLA4 given one week apart.  Four weeks after initial dosing with Cy/PC61, 
booster vaccinations were administered in the same fashion before pancreata 
were harvested for PanIN grading or TIL quantification. 
(B) Quantification of PanIN lesions in KPC pancreata post-drug treatments (9-14 
mice per treatment group)  
      
Triple combination therapy depletes Tregs and reduces the remaining Treg-
specific CTLA-4 expression in the early TME 
Flow cytometric analysis of pancreatic TILs revealed that the total 
proportion of CD4 and CD8 T cells are unchanged in early KPC pancreata as a 
result of combination immunotherapy (Figure 2.4A-B); however, the proportion 
of Tregs in the early TME is reduced the most by triple treatment (8.7%) 
compared to all other treatment groups (Figure 2.4C).  In the pancreata of KPC 
mice that received triple treatment, the proportion of Tregs was reduced by 3-fold 
as compared to mice that received no treatment (30.2%) and 2-fold as compared 
to mice that received LM-Kras in combination with Cy/PC61 and isotype antibody 
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(15.7%).  Moreover, this data indicates that triple treatment also produced the 
largest pool of CD4 T effector cells (CD4+Foxp3- non-Tregs) as a result of Treg 
depletion.  Interestingly, the fewer Tregs that remain as result of triple treatment 
also express lower levels of CTLA-4 than the other remaining Treg pools of all 
other treatment groups (Figure 2.4D).  Therefore, combination triple treatment 
produced the lowest proportion of total Tregs with the least CTLA-4 expression 
on those remaining Tregs.  Triple combination therapy exerts negative 
synergistic effects on Tregs in the early PDA TME, enhancing localized immune 
activation, which may be a mechanism contributing to the delayed progression of 


















Figure 2.4 Total proportions of CD4, CD8, and Tregs present in 
premalignant KPC pancreata as a result of treatment.  
(A) Percentages of CD4+ T cells in TILs 
(B) Percentages of CD8+ T cells in TILs  
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(C) Percentages of Tregs (CD4+Foxp3+) in TILs  
(D) Percentages of Tregs that express CTLA-4 
 
LM-Kras vaccine, Treg depletion, and CTLA-4 blockade reprograms CD4 
and CD8 T cell expression of inhibitory immune signals in early PDA 
development    
After demonstrating that our triple combination treatment reduced the total 
Treg populations and the expression of CTLA-4 by remaining Treg populations 
as compared to all other treatment groups, we assessed whether combination 
immunotherapy affected the expression of other well-characterized immune 
checkpoint molecules programmed cell death protein 1 (PD-1) and lymphocyte 
activation gene-3 (LAG-3), as well as the immune modulating lectin galectin-3 on 
CD4 and CD8 T cells.  We discovered that triple treatment produced the lowest 
proportion of CTLA4+PD1+ CD4 T cells compared to all other groups, and that all 
differences were statistically significant (Figure 2.5A).  Additionally, the 
percentages of CTLA4+PD1- CD4 T cells were significantly reduced by triple 
treatment (13.1%) as compared to no treatment (26.4%), anti-CTLA-4 alone 
(25.6%), and LM-Kras plus anti-CTLA-4 (26.4%).  The proportion of PD-1 single 
positive (CTLA4-PD1+) CD4 T cells did not change due to treatment.  However, 
our data demonstrated that the percentages of PD1 single positive CD8 T cells 
were much greater across all treatment groups as compared to CD4, showing 
that CD8 T cells have higher PD1 expression and are therefore more subject to 
PD1 negative regulation, providing rationale for utilizing PD1 blocking agents to 
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specifically enhance CD8 T cell activation in this model.  Although there were no 
statistically significant differences due to treatment for double positive 
(CTLA4+PD1+) and single positive (CTLA4+PD1- and CTLA4-PD1+) CD8 T cell 
populations, there was a decreasing trend in CTLA4+PD1+ CD8 T cell 
percentages as result of treatment with triple combination therapy producing the 
lowest proportion (6.9%) of CTLA4+PD1+ CD8 T cells compared to all other 
treatment groups. 
Although lower proportions of CD4 and CD8 T cells expressed LAG-3 and 
galectin-3 than CTLA-4 and PD-1, the reprogramming achieved by triple 
combination immunotherapy was still apparent in CD8 T cells.  Triple treatment 
reduced both LAG3+GAL3- CD4 and CD8 T cells percentages as compared to all 
other treatment groups (Figure 2.5B).  The proportion of Galectin-3 single 
positive (LAG3-GAL3+) CD4 and CD8 T cells did not change due to treatment; 
however, only for double positive LAG3+GAL3+ CD8 T cells did triple treatment 
achieve the most percent population reduction compared to all other treatment 
groups.  Additionally, there is a higher overall proportion of double positive 
LAG3+GAL3+ CD8 T cells than CD4 T cells indicating that galectin-3 binds to its 







Figure 2.5          
     
     
Figure 2.5 Triple combination immunotherapy differentially modulates 
expression of CTLA-4, PD-1, LAG-3, and galectin-3 in CD4 and CD8 T cells. 
(A) Percentages of CD4 and CD8 T cells expressing CTLA-4 alone, PD-1 alone, 
or CTLA-4 and PD-1  
(B) Percentages of CD4 and CD8 T cells expressing LAG-3 alone, galectin-3 




LM-Kras vaccine, Treg depletion, and CTLA-4 inhibition activates effector 
CD8 T cells enhancing their cytotoxic phenotype in the premalignant TME  
As a result of Treg depletion, downregulation of inhibitory checkpoint 
molecules and factors, and vaccine-mediated antigen priming of T cells, our triple 
combination therapy significantly increased activation of CD8 T cells as 
compared to all other treatment groups (Figure 2.6A).  CD8 T cell activation was 
quantified by expression of CD44, a cell surface activation marker expressed by 
antigen-experienced lymphocytes.  As a result of triple therapy, the proportion of 
activated CD44+ CD8 T cells increased more than 3-fold (36.9%) as compared to 
no treatment (11.1%).  Additionally, triple therapy produced more than 10% 
increase of activated CD44+ CD8 T cells as compared to LM-Kras and Cy/PC61 
(22.4%) and anti-CTLA-4 alone (23.4%).   
Not only did CD8 T cells of the triple treatment group have the highest 
expression of activation markers, but they also produced the highest levels of 
cytotoxins and effector cytokines, indicative of increased effector function.  The 
production of Granzyme B, a serine protease secreted by cytotoxic T 
lymphocytes (CTLs) to trigger caspase-mediated apoptosis in target cells97, by 
CD8 T cells was significantly increased by triple treatment as compared to all 
other groups (Figure 2.6B).  The proportion of CD8 T cells producing Granzyme 
B as a result of triple treatment increased 3-fold (16.1%) as compared to the no 
treatment group (5.9%) and 2-fold as compared to LM-Kras and Cy/PC61 (7.1%) 
and anti-CTLA-4 alone groups (8.4%).  Triple combination therapy also resulted 
in the highest percentages of CD8 T cells expressing key proinflammatory 
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effector cytokine interferon gamma (IFNγ) as compared to all other treatment 
groups (Figure 2.6C).  Despite relatively high percentages of IFNγ+ CD8 T cells 
in all treatment groups, tumor necrosis factor (TNFα) was produced to a much 
lower degree and its expression on CD8 T cells did not change as a result of 
treatment.  This observation can be explained in part due to TNFα’s predominant 
production and secretion by macrophages, whereas IFNγ is one of the major 



















       
                         
Figure 2.6 Triple combination immunotherapy increased CD8 T cell 
activation and production of Granzyme B and IFNγ  
(A) Percentages of CD8 T cells expressing CD44  
(B) Percentages of CD8 T expressing Granzyme B 
(C) Percentages of CD8 T cells expressing IFNγ alone, TNFα alone, or IFNγ and 
TNFα  
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CTLA-4 blockade combined with Treg depletion during vaccine-mediated 
priming in early PDA progression enhances CD8 memory populations and 
T effector to Treg ratios conferring long term protection 
  Our research thus far has been investigating the altered early-stage 
immune-mediated mechanisms that result from combination immunotherapy in 
the context of early disease intervention.  We next sought to explore how triple 
treatment would affect memory populations and other prognostic immune 
indicators of long term protection.  We assessed how combination treatment 
affected CD8 T cell memory populations as defined by CD44, indicating antigen-
experienced, and CD62L (L-selectin), an adhesion molecule commonly on T cells 
that traffics populations to secondary lymphoid tissues to reside until re-
encountering with cognate antigens.98  Memory CD8 T cells are therefore defined 
as being a CD44+CD62L+ population.  We discovered that triple treatment 
produced the highest percentages of memory CD8 T cells as compared to all 
other groups (Figure 2.7A) indicating that our combination therapy was able to 
convert 35% of total CD8 T cells present in the early PDA TME to effector 
memory populations for continual long-term immunity against mutant KRASG12D. 
 CD8 T cell to Treg ratio (Teff:Treg ratio) in TILs has proven to be an 
effective prognostic indicator of overall survival in many cancer models, and a 
higher Teff:Treg ratio in patient TILs correlate with better prognosis, longer 
overall survival, and better patient response to immunotherapy in many human 
GI cancers including PDA.99–102  In our study, KPC mice that received triple 
treatment had the highest Teff:Treg ratio as compared to all other treatment 
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groups (all differences were statistically significant) (Figure 2.7B).  The ratio from 
triple treatment TILs (9) was more than 2-fold higher than that of LM-Kras and 
Cy/PC61 (4) and more than 4-fold higher than that of anti-CTLA-4 alone (2) or no 
treatment (2).  The increased Teff:Treg ratio for our triple treatment group is not 
due to increased infiltration of CD8 T cells in our model, since our data 
demonstrated that the total proportion of CD8 T cells in the early TME was not 
changed due to treatment.  Rather, it is the significant depletion of Tregs as a 
result of combination therapy that largely increases the ratio.  These data 
suggest that our triple combination therapy successfully reprograms the early 
PDA TME to shift the balance of Teff:Treg ratio in favor of an early antitumor 
immune response.  Additionally, for the first time, we report that high Teff:Treg 
ratio is also a good prognostic indicator of premalignant progression in early 













                    
                     
Figure 2.7 KPC mice that received triple combination therapy developed 
increased memory CD8 T cell population and higher Teff:Treg ratios.  
(A) Percentages of CD8 T cells expressing CD44 alone, CD62L alone, or CD44 
and CD62L 
(B) CD8+:CD4+Foxp3+ ratio determined from each KPC pancreas 
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DISCUSSION 
PDA is considered an immunologically “cold” cancer due to its low 
mutational burden and extensive stromal reaction that creates a TME that 
propagates and protects the tumor from chemotherapeutic and 
immunotherapeutic penetration.79  Due to the non-immunopermissive nature of 
the PDA TME, single agent immunotherapies have not been successful at 
eradicating the tumor.  In addition to the dense fibrotic stroma that constitutes an 
immense physical barrier that immune cells must penetrate, there are multitudes 
of inhibitory immune populations and immunosuppressive checkpoint molecules 
within the TME that function to turn off the immune system.  Pathways and 
signaling mechanisms that normally prevent auto-immunity and are essential for 
tissue homeostasis are hijacked by the tumor to evade recognition and 
eradication by the immune system.  Therefore, multiple agent combination 
therapies that simultaneously target many cellular and acellular components 
must be employed to achieve a robust immunologic attack on the developing 
tumor and TME.  
 Our group previously reported that the use of a Listeria monocytogenes  
bacteria-based vaccine expressing driver mutation KRASG12D (LM-Kras) in 
combination with Cy and PC61 to deplete the early PDA TME of 
immunosuppressive Tregs, significantly delayed PanIN progression and shifted 
the immune profiles in the early TME to that of a more proinflammatory antitumor 
phenotype.  In this study, we aimed to improve the immunopreventative potential 
of the previously formulated combination therapy by supplementing with anti-
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CTLA-4 checkpoint blockade to further deplete Tregs and inhibit this negative 
regulator of T cell activation.  Histological analysis of PanIN lesions in KPC 
pancreata revealed that our combination immunotherapy supplemented with 
CTLA-4 blocking antibody, was successful in further intercepting PanIN 
progression as evidenced by the failure of lesions to advance beyond low-grade 
PanIN1.  Encouraged by these improved results, we sought to understand the 
cellular mechanisms that are modulated by our triple combination therapy to 
achieve more effective disease prevention.     
 Flow cytometry of TILs isolated from treated KPC mice revealed that LM-
Kras vaccine administered in combination with Treg depleting agents and CTLA-
4 blockade reprograms CD4 and CD8 T cells in the early PDA TME into more 
activated effector phenotypes by significantly depleting the population of 
immunosuppressive Tregs and reducing the expression of several inhibitory 
checkpoint molecules in the premalignant TME.  Adjuvant immune modulation of 
Tregs and checkpoints aids the priming of the T cells to mount a more robust 
adaptive immune response against the target antigen, mutant KRASG12D, one of 
the earliest gene products of the driver mutation that initiates PDA tumorigenesis 
and causes subsequent oncogene addiction that drives premalignant 
progression.3  While our study achieved successful PanIN interception, the true 
prophylactic potential of our combination therapy may be more accurately 
assessed by using an inducible KPC mouse model in which vaccine regimen can 
be administered prior to the induction of mutant KRASG12D expression, allowing 
antigen-engagement by the adaptive immune system before exposure to the 
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causative antigen.  Such a model would be more accurate and a true translation 
of prophylactic vaccines for infectious tumors to non-infectious tumors.  Jing Pan 
et al. demonstrated that administration of a multi-peptide KRAS vaccine before 
induction of mutant KRASG12D expression in an inducible CCSP-TetO-KRASG12D 
mouse model of lung cancer led to more than 80% reduction of primary lung 
tumor number and volume that coincided with peripheral immunologic responses 
to specific immunizing peptides.103  The results from this study along with the 
results obtained from our study of targeting mutant KRASG12D in early PDA 
development demonstrates that such a vaccination approach can be utilized for 
the primary prevention of other KRAS-driven cancers.        
  Quantification of CD4 and CD8 T cells from treated KPC TILs revealed 
that the total number of each T cell subset was not increased due to treatment.  
This may be due to the nature of T cell depletion of low dose Cy.  Cy exerts its 
Treg depleting specificity due to Treg’s high proliferation in both early and 
established PDA which causes Tregs to be the most sensitive to Cy toxicity.83  
However, when using immunomodulatory agents that activate the immune 
system, other effector T cell subsets will expand and proliferate, making them 
susceptible to Cy toxicity as well.83  Another mechanism of action that can 
explain lack of increased CD4 and CD8 in the TME is Cy’s ability to increase 
immunosuppressive MDSCs that can deactivated T cells thereby preventing their 
proliferation and expansion.75,83  This dual effect of low dose Cy provides 
rationale for concurrent use of MDSC inhibiting agents to further enhance 
immune activation.    
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Our triple combination therapy depleted the most Tregs from the early 
PDA TME while reducing the most CTLA-4 expression on the remaining pool of 
Tregs out of all treatment groups.  Our data demonstrates that the 
supplementation of anti-CTLA-4 antibody not only effectively diminished the raw 
numbers of Tregs, but that CLTA-4 blockade further decreased their specific 
CTLA-4-mediated inhibitory capabilities.  Additionally, our data is consistent with 
previous studies that report the extremely high constitutive expression of CTLA-4 
by Tregs.  Out of the total Tregs isolated from KPC mice that received no 
treatment, nearly 100% of untreated isolated Tregs expressed CTLA-4, 
underscoring the potent immunosuppressive functionality of Tregs and the need 
for blocking CTLA-4 on this extremely inhibitory immune population.    
Analysis of immune checkpoint expression on CD4 and CD8 T cells, 
revealed that triple treatment lowered the proportion of CTLA4+ CD4 and CD8 T 
in the early PDA TME.  Treatment with all three immunotherapeutic components 
in combination produced the highest level of CTLA-4 blockade as compared to all 
other treatment groups that will allow T cells in the early TME to be subject to 
less negative regulation and be less driven towards anergy.  Currently, we are 
utilizing Nanostring to quantify the transcript abundance of these checkpoint 
molecules along with other regulators in immune signaling pathways to assess 
how combination treatment modulates mRNA expression.  Our data shows that 
the protein levels of CTLA-4, both extracellular receptors and intracellular 
reserves, are reduced the most with treatment.  We also want to assess whether 
levels of CTLA-4 mRNA expression is modulated in the same way. 
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The lower percentages of LAG3+GAL3+ CD8 T cells in the early PDA TME 
as a result of triple combination therapy may further contribute to the concurrent 
increased proportion of activated effector CD8 T cells with effector phenotypes, a 
finding that has been previously corroborated by other groups.104–106  Galectin-3 
binds to LAG-3 which leads to sequestering of the CD8 T cell receptor (TCR) and 
dissociation from its co-receptor producing non-functional CTLs.106,107  Since 
galectin-3 directly binds to LAG-3, an association required for galectin-3 to 
mediate its immunosuppressive functions in the TME, it makes sense that 
decreased populations of LAG3+GAL3+ CD8 T cells would coincide with 
decreased populations of LAG-3+ CD8 T cells, although the mechanism as to 
how our triple treatment is mediating the decreased expression of LAG-3+ on 
CD8 T cells is unknown and warrants further investigation.  The 
immunomodulation in this study predominantly targets CD4 T cells, but the high 
expression of PD-1 and substantial expression of LAG-3 checkpoints specifically 
on CD8 T cells indicates that future studies should supplement with blockade of 
these checkpoints to enhance immune activation and effector CD8 T cell 
function.      
We report for the first time that early LM-Kras vaccine-mediated priming of 
T cells in combination with Treg depletion and CTLA-4 blockade effectively 
produced a substantial population of memory CD8 T cells in the early PDA TME 
that will confer continual and long-term protection against developing mutant 
KRASG12D driven neoplasms in KPC mice.  This mechanism of protection against 
early premalignancies may contribute to the delayed PanIN progression seen in 
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triple treated KPC mice.  Our study also revealed that early administration of 
triple therapy significantly increased the Teff:Treg ratio which is a prognostic 
indicator of overall survival and robust immune response to combination therapy 
in human PDA.  However, we have shown that this metric can also be applied to 
assess the efficacy of prophylactic immunotherapy in preventing early 
premalignant progression, not just in established PDA.   
Beyond just quantifying the amount of specific immune populations and 
markers in the early TME, we are performing IHC to assess the spatial 
localization of these populations in association to specific structures in early PDA 
development.  Such studies will reveal how combination treatment modulates the 
spatial recruitment of specific T cell subsets to varying grades of PanIN lesions.  
Additionally, we are performing TCR sequencing to see if TCR diversity and/or 
clonality is affected by treatment, which would provide deeper mechanistic insight 
as to how our triple combination therapy is enhancing immunity to 
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progression. 
Status: In preparation 
3.  Chu NJ, Cao M, Anders R, Jaffee EM. Serum miRNA signatures for the 
early detection of premalignant lesions in a developmental model of 
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Status: In preparation 
 
HONORS AND AWARDS 
 
WOMEN IN CANCER RESEARCH SCHOLAR AWARD 
April 2018 
American Association for Cancer Research Annual Meeting 2018, Chicago, IL 
 
1ST PLACE WINNER, BASIC RESEARCH CATEGORY 
SKCCC Fellow Research Day                                                                                       
May 2017 
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD  
 
YOUNG INVESTIGATOR TRAVEL FELLOWSHIP AWARD                                        
Oct. 2014 
Symposia on Cancer Research 2014, Illuminating Genomic Dark Matter “ncRNA 
in Disease and Cancer” MD Anderson Cancer Center, Houston, TX 
 
PRESENTATIONS AND CONFERENCES 
 
1.  Oral Presentation: American Association for Cancer Research Annual 
Meeting 2018. April 2018. Chicago, IL 
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3.  Poster: Bloomberg-Kimmel Institute for Cancer Immunotherapy Scientific 
Retreat. June 2017. Baltimore, MD  
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Chu NJ, Armstrong TD, Jaffee EM. Novel miRNA regulation in an early 
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Chu N, Goyal R, Goyal D, Longo LD. Maturation and Differential Role of 





American Association for the Advancement of Science 
American Association for Cancer Research 




FOUNDING MEMBER: Pharmacology Student Initiative March 2015-present 
Johns Hopkins University School of Medicine, Pharmacology Department, 
Baltimore, MD 
• Leads a student-run departmental organization that aims to: enhance 
student-faculty relations, facilitate better student camaraderie, increase 
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student involvement in departmental events, represent pharmacology 
student interests to the faculty and vice-versa 
• Lead annual departmental recruitment resulting in 60-70% confirmation of 
desired applicants within 5 days of admission offer 
• Organized, executed, and publicized departmental social events, annual 
departmental retreat, new-student orientation, professional development 
workshops, alumni events, diversity initiatives, community service 
opportunities, and student forums   
 
COUNSELOR: UCLA Unicamp               Jan. 2007-July 2007 
University of California Los Angeles, Los Angeles, CA   
• Mentored 13-year-old girls from low-income families as part of UCLA 
Unicamp, the university’s official student non-profit organization 
• Led activities that emphasized responsibility, cooperation, and positivity 
with the goal of empowering children at UCLA’s outdoor summer camp 
• Fundraised to provide all costs of attending camp for both my campers 
and myself 
 
MEMBER: Bruin Leaders Project            Sept. 2003-June 2007 
University of California Los Angeles, Los Angeles, CA 
• Participated in this hands-on, seminar-based leadership development 
program that strives to make its participants better students, better 
leaders, and better citizens 
• Engaged in programs that focused on social change, diversity, ethics, 
public speaking, and conflict management 
 
COMMUNICATIONS COMMISSIONER: On Campus Housing Council 
University of California Los Angeles, Los Angeles, CA        Sept. 2004-June 2005 
• Programmed, produced, and publicized events for all students living on 
campus 
• Wrote monthly informational newsletters concerning campus wide events. 
• Worked dynamically with a group of student leaders to represent the 
concerns of the student body to housing professionals and to serve as a 
liaison between on-campus housing and other UCLA entities. 
 
AREAS OF EXPERTISE 
 
• Molecular biology: construct generation, transfection, transformation, 
transduction, qPCR, western blot, monoclonal antibody production and 
purification 
• Cellular/Tissue imaging and analysis: IF, FISH, IHC, multi-color flow 
cytometry, FACS, proliferation/migration/invasion assays, confocal 
microscopy, laser capture micro-dissection, pathological grading of 
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premalignant lesions and PDA tissue, fluorescent Ca2+ imaging, 
measurement and quantification of smooth muscle arterial contractility 
•  Establishment and maintenance of primary cell lines 
•  In vivo modeling: syngeneic mouse models, drug efficacy studies, drug 
formulations and dosing (PO, IP, IV, SC), blood and tissue collection, 
maintenance and propagation of mouse colonies 
•  Analysis and interpretation of microarray data 
•  Software: GraphPad Prism, ImageJ, ExpressionSuite, FlowJo, HALO, 
STATA, Microsoft Office 
•  Strong ability to work in a collaborative, dynamic, and multi-disciplinary 
environment 
 
  
 
